Abstract: Bovine leukemia virus (BLV) is a retrovirus closely related to the human T-lymphotropic virus type 1 (HTLV-1). BLV is a major animal health problem worldwide causing important economic losses. A series of attempts were developed to reduce prevalence, chiefly by eradication of infected cattle, segregation of BLV-free animals and vaccination. Although having been instrumental in regions such as the EU, these strategies were unsuccessful elsewhere mainly due to economic costs, management restrictions and lack of an efficient vaccine. This review, which summarizes the different attempts previously developed to decrease seroprevalence of BLV, may be informative for management of HTLV-1 infection. We also propose a new approach based on competitive infection with virus deletants aiming at reducing proviral loads.
1. Introduction

As early as in the 19th century, a series of reports already described the occurrence of clinical signs associated with enzootic bovine leukosis (EBL). Initial observations from Leisering of yellowish nodules in the enlarged spleen of a leukocytic cow were communicated in the German literature in 1871 ([1], cited by [2]). Three years later, Bollinger described bovine leukemia as a well-defined clinical entity, and in 1876 Siedamgrotzky and Hofmeister recorded the first cases of bovine lymphocytic malignancies ([3,4]; cited by [2]). Thus, Europe, and more specifically the Memel area, then regarded as East Prussia and now located in the contemporary Lithuania, might be thought of as the cradle of enzootic bovine leukemia ([5]; cited by [6]). Diffusion and wide spread of the disease occurred by the introduction of European cattle breeds in countries free of the disease. Despite all these pieces of evidence, the infectious nature of EBL etiological agent was discovered many decades later based on epidemiological evidence [7]. Finally, the causative agent of this malignant disease was isolated in culture in 1969 [8] and designated bovine leukemia virus (BLV).

BLV is an oncogenic B-lymphocytotropic retrovirus that infects cattle inducing a persistent infection with diverse outcomes [9–16]. The great majority of BLV-infected animals (around 70%) are asymptomatic carriers of the virus. In these animals, neither clinical symptoms nor alteration of the total lymphocyte count are evidenced. Thus, they can only be identified by the presence of anti-BLV antibodies and/or of proviral DNA [14,16]. Approximately, one-third of BLV-infected bovines develop a benign polyclonal proliferation of B cells called persistent lymphocytosis (PL). This clinical condition is characterized by an increase in the absolute number of peripheral blood circulating B lymphocytes associated with an inversion of the B/T lymphocyte ratio [9,14,17,18]. Despite these hematologic alterations, PL animals do not develop any other apparent clinical signs. PL is usually stable for several years but can also progress to the tumor phase [9,14,18].

The most conspicuous clinical manifestation of BLV infection is the development of lymphoid tumors. Fatal lymphoma or lymphosarcoma (LS) occurs in less than 5–10% of infected animals, predominantly adult cattle older than 4–5 years old [10,14]. The development of tumors is not necessarily preceded by a phase of PL, but this is the case in two-thirds of the animals [14,19]. Unlike persistent lymphocytosis, B-cell expansion is of mono- or oligo-clonal origin [13,14,20–24]. Local proliferation of B cells, called lymphosarcoma, can occur within different organs and tissues leading to a series of defects that are finally incompatible with the survival of the animal. In addition, transformed B cells can also induce the enlargement of lymph nodes and cause lymphoma [10,14]. Besides an impact on survival, BLV infection also impairs the immune system leading to opportunistic infections [25–27].

2. Transmission

BLV is transmitted horizontally, essentially through the transfer of infected cells [28]. Since free virus is very unstable, BLV-infected cells (B-lymphocytes, monocytes/macrophages, etc.) present in
blood or milk appear to be the best vehicles of natural transmission [16]. Due to the high number of infected cells they contain, animals with PL are particularly efficient in transmitting the virus [28]. In herds, iatrogenic procedures largely account for the propagation of the infection. Cattle management procedures which involve transfer of infected blood (i.e., dehorning, ear tattooing, rectal palpation, and, essentially, the use of infected needles) were postulated as a common mode of transmission [29]. In addition, prolonged direct contact between infected and healthy animals has also been considered as a risk factor for BLV transmission. Transfer of infected blood might also occur in regions with high density of hematophagous insects [30,31]. Perinatal or postnatal transmission of BLV frequently happens in herd conditions. The rate of transmission in utero varies between 4 and 18% [32–34], with highest risk in calves born from cows with PL [35]. Although BLV transmission has been postulated to occur from cow to calves via milk, this route of infection was only demonstrated experimentally [36–38]. Despite the presence of BLV proviral DNA in colostrum and milk from infected cows, calves can remain uninfected over extended periods of time likely due to the protective role of maternal antibodies present in the colostrum [39–41].

3. Epidemiology

Sero-epidemiological surveys have shown that BLV infection is widespread in all continents except in Europe. Efforts in the implementation of control measures and campaigns to eradicate BLV infection in Western Europe have been successful [42–45]. Recently, the European Economic Community (EEC) declared most of its member states as officially free of EBL. In contrast, the situation is different in Eastern Europe where the disease is still present in several countries (Bulgaria, Croatia, Estonia, Latvia, Poland, Romania, Ukraine) [46].

Similar attempts to eradicate BLV infection in Australia and New Zealand dairy herds began in the mid-1990s. More than 98% of dairy herds were negative in 2005 [47,48].

Detailed information about the epidemiological situation in the United States of America was collected through the National Animal Health Monitoring (NAHMS). Survey studies in 2007 revealed that 83.9% of U.S. dairy herds were positive for BLV [49]. Recent epidemiological data is available for several provinces in Canada. All agree in indicating high seroprevalence rates reaching up to 89% and 20.8%–37.4% at herd and individual levels, respectively [50–54].

In South America, individual infection rates between 34 and 50% were reported in Colombia, Venezuela, Chile and Uruguay [55–58]. In Argentina, individual and herd prevalence levels scale up to 32.8% and 84%, respectively [59]. In Brazil, the individual prevalence of BLV infection varies considerably among states and reaches levels beyond 50% [60–67].

The epidemiological situation in Asia is more uncertain. The International Organization of Epizootics (OIE) recognizes that BLV is present in Indonesia, Taipei (China) and Mongolia [46]. Surprisingly, only about 5% of animals were positive for BLV in Cambodia and Taiwan [68,69]. The seroprevalence rates in Japan were found to be 28.6% and 68.1% at the individual and herd levels, respectively [70]. In Korea, individual seroprevalence rates exceeded 50% whilst 86.8% of dairy herds were infected [71].

Regarding the Middle East countries, reports indicate that the prevalence of BLV infection is somewhat lower than in other regions of the world, i.e., about 20% [27,72–74]. Exceptions in this
region include Turkey and Iran where the herd seroprevalence levels climb to 48.3% and 64.7%, respectively, while the individual seroprevalence in Iran was estimated between 17 and 24.6% [75–77], although some argue that prevalence levels are lower [78].

4. Preventive and Therapeutic Strategies

Understanding the mechanisms of pathogenesis has been instrumental for developing therapeutic and preventive strategies against BLV infection. The different approaches that were developed are reviewed in this section.

4.1. Removal or Segregation Approaches

4.1.1. Test and Eliminate

A first strategy is to identify and eliminate BLV-infected cattle. This approach requires identification of BLV-positive animals either by hematological, genomic or serological methods, immediate removal of positive cases from the herd and, finally, prompt slaughtering [7,79,80].

This “test and elimination” methodology has been instrumental in accomplishing the BLV-free status at herd and regional scales within a relatively brief period of time when compared to other alternatives [7,43–45,81–89]. Evidence of the efficiency of this strategy is illustrated by the successful eradication of the disease in several countries of Western Europe.

Although this approach has been efficient, its feasibility faces some important restrictions. A key limitation is that the initial prevalence rate of infection should not be high due to its very high economic cost. Hence, this strategy can be particularly justified in pedigree breeds having high genetic potential as well as for export to BLV-free countries. Nevertheless, even when the rates of infection are low, the “test and eliminate” approach is a burdensome strategy due to diagnostics, premature culling and replacement of reactors. Loss of genetic and reproductive potential must also be considered.

In fact, this strategy requires governmental economic compensation policies to be successful. If no official subsidizing action is adopted by the local authorities, the costs of implementation of such a strategy quickly exceeds the potential benefits. Countries such as USA, Canada, Argentina, and Japan lacking financial compensatory policies usually failed to obtain adherence to enroll in these programs [49–54,59,70,90,91].

To summarize, the pros and cons of the “test and eliminate” strategy are outlined in Table 1.

4.1.2. Test and Segregate

Another approach aims at reducing part of these costs by segregating instead of culling infected animals. Control programs based on segregation require detection of seropositive animals and confinement of BLV-infected and seronegative herds in strictly separated areas [28,92,93]. It has been proposed that a minimum distance of 200 meters must separate the two herds to avoid transmission [92]. An alternative option is to keep the animals in the same farm and to manage them separately. For optimal results with any of these options, separate equipment or at least careful disinfection and hygiene of non-disposable equipment should be implemented (Table 1). The main advantage of this approach is the reduction of costly losses due to compulsory premature culling and replacement of
BLV-positive animals. Although quite demanding, this type of program has been useful to decrease prevalence or even achieve eradication of the disease [84,92,94]. The disadvantage is that there is a permanent risk of reintroducing infected animals and, therefore, it may be slower than the ‘test and eliminate’ option [95].

Table 1. Currently available approaches for bovine leukemia virus (BLV) control and prevention.

| APPROACH         | BASIS OF THE CONTROL PROGRAM                                      | ADVANTAGES                                                                 | DISADVANTAGES                                                                 |
|------------------|---------------------------------------------------------------------|-----------------------------------------------------------------------------|------------------------------------------------------------------------------|
| TEST AND ELIMINATE | Identify BLV-infected cattle and slaughter positive reactors         | Efficient                                                                  | May become cost-prohibitive and impracticable depending on the initial prevalence levels |
|                  |                                                                     | Requires only minimal investment on facilities                              | Needs constant surveillance                                                  |
|                  | BLV-free status might be achieved in a relatively short period       |                                                                             | Requires official compensatory policies to be successful                    |
| TEST AND SEGREGATE | Detect and isolate BLV-infected cattle in separate herds             | Needs structural and operational accommodation of infected and non-infected cattle in strictly separated areas | Increases costs due to duplicated housing facilities and equipment            |
|                  | Manage separately infected and non-infected cattle in the same housing facilities | Does not need replacement of culled BLV-infected cattle                     | Requires permanent surveillance                                               |
|                  |                                                                     |                                                                             | Needs long-term commitment to the program                                    |
| TEST AND MANAGE  | Take biosafety and management measures to minimize exposure of animals to the infectious agent | Cost-effective                                                             | Intensively laborious                                                        |
|                  |                                                                     | Requires only minimal investment on facilities                              | Requires strict adherence to the rigorous implemented measures               |
|                  |                                                                     | Does not need replacement of culled BLV-infected cattle                     | Needs long-term commitment to the program                                    |
|                  |                                                                     |                                                                             | Susceptible to human and environmental factors                              |
|                  |                                                                     |                                                                             | Needs adequate training of personnel                                          |

The removal/segregation approaches both require specific and regular identification of infected animals. Discrimination of BLV-infected animals from the herd was originally performed by hematologic screening based on leukocyte counts [7]. Later on, more sensitive and specific techniques (i.e., AGID, agar gel-immunodiffusion test and ELISA, enzyme-linked immunosorbent assay) became routine diagnostic methods. These serologic assays performed on serum or milk were widely used and became the official tests recommended for international trade [96]. However, these tests can be misleading since the presence of anti-BLV antibodies does not necessarily imply that the animals are infected and vice versa. Indeed, there is a “latency” period of several weeks between infection and
seroconversion [97]. Also, calves can have anti-BLV antibodies due to maternal antibodies from the colostrum [33,36,39,98,99] or to parturition [99]. A significant fraction of these calves will remain uninfected although they carry anti-BLV antibodies.

Therefore, a more accurate way to monitor BLV infection is PCR [100,101]. BLV-infected cattle can further be classified according to their proviral load (PVL) [102]. In fact, the proviral load in the peripheral blood is a predictive marker of transmission risk. Thus, PVL can be used as a criterion to discriminate and eliminate/segregate highly infected cows [102–104]. Besides technical challenges (contaminations), the disadvantages of PCR-based diagnostics are higher costs and the need of more complex equipment.

4.2. Corrective Management and Veterinary Practices

This type of approach aims at limiting transfer of BLV-infected cells present in blood, milk, secretions, excretions, syringes or surgical instruments.

Among the diverse control measures that can be implemented in a preventive or corrective management control plan, the following constitute essential practices:

- (i) use of individual, single-use needles and syringes during vaccination or therapeutic protocols;
- (ii) use of individual, single-use obstetrical sleeves (or at least replacement between examination of BLV-reactors and non-infected animals);
- (iii) use of disposable equipment (or at least cleaning, disinfection or sterilization of reusable materials and surgical instruments) in procedures such as dehorning, tattooing, implanting, cauterizing, castration or ear-tagging;
- (iv) use of electrical or gas burning devices rather than gouging equipment during dehorning;
- (v) feeding calves with colostrum or whole milk from non-infected dams, pasteurized colostrum from BLV-infected cows or milk replacer;
- (vi) elimination of insects, particularly in densely populated farm areas (milking areas, free-stalls, barns) in order to minimize potential transmission between animals through arthropod vectors;
- (vii) natural and/or artificial insemination and embryo transfer with BLV-free dams and bulls.

Other potentially beneficial management control measures might include: (i) prevent introduction of infected animals into the herd by testing and quarantining/isolating newcomers; (ii) separate animals by age to decrease contacts (iii) minimize movement of animals between milking/feeding groups; (iv) use individual calf hutches for newborn calves; and (v) limit access to outside visitors.

Compared to the test and eliminate/segregate strategies, the “corrective management and veterinary practices” approach is clearly more cost-effective. Neither investments on facilities nor removal of infected cattle nor constant surveillance of the herd serological status are required. The disadvantages of the corrective management approach are that practices are intensively laborious and vulnerable to environmental and human variables. In this regard, careful appraisal of the effort required before the enrolment into a corrective management control plan must be considered. Strict compliance to the rigorous measures should be enforced and a long-term engagement with the program is required until fruitful benefits of this strategy are observed (see Table 1). In addition, adequate training of personnel
and farm employees on BLV prevention and biosecure practices might be considered. The efficacy of a “corrective management and veterinary practices” strategy based exclusively on strict sanitary measures is still controversial [104–106].

4.3. Selection of BLV-Resistant Cattle

Livestock breeding programs exploit selection of genetic traits beneficial for production (e.g., milk yield, growth, reproduction) [107,108]. In principle, it would be possible to select breeds that are less susceptible or even resistant to BLV infection. Immune responsiveness and heritable resistance or susceptibility to infection are influenced by the host major histocompatibility complex (MHC) [107–110]. The Bovine Lymphocyte Antigen (BoLA) refers to the major histocompatibility complex in bovine species (Bos taurus and Bos indicus) [111–113]. Pioneering work suggested that host genetics factors determined cattle susceptibility to BLV infection [114]. Early studies initially attributed a linkage between resistance or susceptibility of cattle to development of subclinical PL and serologically defined class I BoLA-A alleles [115]. However, frequencies of BoLA-A alleles diverge considerably between breeds [116–119] and the association was not confirmed at the population level [117]. More sensitive analyses showed that the development of PL was apparently more closely related to class II DRB2 genes [120]. Further characterization of genes within the class II BoLA locus evidenced that the strongest association with resistance or susceptibility to PL corresponded to polymorphisms of the class II DRB3 gene [121,122], the only one actively transcribed among the three DRB genes [123]. Reduced proviral loads were observed in animals carrying the resistance-associated DRB3.2*11 allele, conferring biological significance to this association [124]. These observations were later confirmed and extended to other breeds [125,126]. More recently, a strong linkage between the allele DRB3.2*0902 and genetic resistance to PL was demonstrated in Holstein cows [127]. The presence of DRB3.2*0902 allele correlates with a low proviral load profile (LPL). It was proposed that cattle harboring the *0902 allele and presenting this LPL profile might be unable to transmit BLV in herd conditions [102]. Polymorphisms in the BoLA-DRB3 genes were also correlated with resistance and susceptibility to leukemia/lymphoma in cows [116,126,128,129]. In the experimental sheep model, gene polymorphisms of ovine leukocyte antigen (OLA)-DRB1 can predict the frequency of tumor development [130].

Besides the polymorphic BoLA-DRB3 gene, other non-MHC genes are also considered to be involved in the development or progression of BLV infection. An association between TNF-alpha and BLV pathogenesis has been established in ovine [131] and bovine species [132]. In the latter, a polymorphism in the promoter region of the TNF-α gene (allele -824G) might contribute to PL susceptibility [132]. Furthermore, polymorphisms in alpha-albumin genes might also be associated with resistance to BLV infection [133].

Selection of BLV resistant animals based on genetic traits faces a series of limitations. First, the relevance and statistical significance of the identified markers must be analyzed at the population level. Large-scale studies in different breeds are required to assess the efficiency and the consequences of selection based on these markers. It is likely that identification of other BoLA polymorphisms or resistance genes will be required to achieve robust and efficient selection. Genetic resistance to BLV infection appears to be a complex mechanism under the control of multiple genes, each contributing
slightly to the phenotype [110,134,135]. Poor correspondence between the specific alleles and development of PL or LS [103,122,127] clearly indicates that other viral or host genetic, epigenetic and/or environmental factors contribute to the outcome of infection [136,137]. In this scenario, it might become difficult to prioritize one allele over other/s as an absolute genetic selection marker for selecting BLV resistant cattle [103].

A second limitation is that selection of BLV-resistant animals encounters a major risk due to the narrowing of the genetic pool of the cattle population. This loss of biodiversity is particularly important in resistance to other pathogens [137,138]. On the other hand, selection for BLV resistance may also have adverse effects on beneficial productivity traits. In this sense, it should be mentioned that humoral immune response to other economically important viral diseases (i.e., foot and mouth disease, bovine herpesvirus type 1 and bovine viral diarrhea virus) was not adversely affected in bovines carrying the DRB3.2*0902 allele [139]. Perhaps a more important problem is that selection based on disease resistance might also have adverse effects on productivity traits [134,138].

Due to these limitations, the benefits of selection programs for BLV resistance might not reach a positive benefit:cost ratio.

4.4. Epigenetic Modulation of Viral Expression as Therapy

This type of approach issued from fundamental research on viral dynamics in BLV-infected sheep. Conceptually, the host-pathogen interplay during infection is characterized by a very dynamic kinetics resulting in a subtle equilibrium between the virus, which attempts to replicate, and the immune response, which seeks to exert tight control of the pathogen. This equilibrium appeared to be tightly regulated by epigenetic mechanisms. In particular, the extent of chromatin condensation is an essential epigenetic control mechanism determining gene expression and is partly dependent on the level of histone acetylation. In a certainly oversimplified model, chromatin relaxation results from acetylation of the conserved N-terminal histone tails that reduces the interaction with the negatively charged phosphate backbone. This allows unwinding of DNA, leading to gene expression by favoring access of transcriptional activators to their target sites. Conversely, gene silencing or transcriptional repression is the consequence of preventing access of transcriptional activators due to DNA packaging into condensed chromatin. This is mediated by acetyl removal of lysine residues from histone N-terminal tails, restoring a positive charge and increasing the affinity of histones for DNA. The degree of acetylation of the core histones reflects an intrinsic balance between the activities of two families of functionally antagonistic enzymes: histone deacetylases (HDACs) and histone acetyltransferases (HATs), which withdraw or incorporate acetyl groups into core histones, respectively [140–146].

In BLV infected cells, the virus is stably integrated apparently in a transcriptionally silent state [147–154]. Two epigenetic mechanisms, histone acetylation and DNA hypermethylation, correlate with BLV transcriptional repression [149,155–160]. The lack of viral expression in a large proportion of infected cells prevents efficient clearance of the virus by the immune system despite the presence of a vigorous immune response. The rationale of a potential therapy consists in inducing viral expression in provirus-carrying cells, thereby exposing infected cells to the host immune response. A key observation for this working model was that increasing the BLV promoter efficiency paradoxically
decreases proviral loads [161]. In this context, a therapeutic approach based on the modulation of host epigenetic mechanisms was proposed to treat BLV infection and disease [159,162,163]. Different HDAC inhibitors (valproate VPA, trichostatin A TSA, trapoxin TPX) efficiently enhance viral transcription directed by the BLV promoter in vitro [155,159]. HDAC inhibitors also increase viral expression during ex vivo short-term culture of peripheral blood mononuclear cells (PBMCs) from BLV-infected sheep and cattle [155,159]. Consistent with its inhibitory activity, VPA induces hyperacetylation of histone H3 [164]. VPA treatment, in the absence of any other cytotoxic drug, induced tumor regression in BLV-infected sheep and was efficient for leukemia/lymphoma therapy in the sheep model. However, VPA treatment was inefficient in preventing primary infection and reducing PVL in asymptomatic sheep [159].

The efficacy of VPA in BLV-infected cows is presently unknown. However, large scale treatment of BLV infected herds with HDAC inhibitors such as VPA is not justified mainly due to costs. Nevertheless, a treatment with VPA, alone or possibly in combination with antiretroviral drugs (AZT) may still be useful to treat animals with high genetic value.

This strategy might also hold promise for treating adult T cell leukemia (ATL) or human T-lymphotropic virus-associated myelopathy/tropical spastic paraparesis (HAM/TSP), diseases for which no satisfactory treatment currently exists (see Section 5) [165,166]. It is noteworthy that VPA alone had no effect in simian T lymphotropic virus type 1 (STLV-1) infected monkeys but significantly reduced the PVL when combined with AZT [167].

4.5. Vaccination

During the last few decades, a series of attempts were performed to develop a vaccine against BLV [11,16,168–170].

4.5.1. Inactivated Virus Vaccines

Early studies evaluated preparations of inactivated BLV obtained from persistently infected cell lines (fetal lamb kidney or FLK, LK15, Bat2C11 cell lines) [171–175]. Inactivation was obtained by treatment of the virus with different chemical agents (N-acetylenimidaine, 0.1% Triton X-100, 0.1% formalin, formaldehyde, aminomethylated compounds). These inactivated virus vaccines induced a strong specific neutralizing humoral response and partially protected sheep and cattle from low dose viral challenge [171,172,175]. Protection roughly correlated with the efficiency of the vaccine to induce a strong neutralizing humoral response. However, vaccinated animals became infected with high challenge doses.

4.5.2. Cell-Derived Vaccines

Several tentative vaccines were based on cell lysates from:

- plasma membranes or cell extracts from BLV tumors [176,177].
- BLV-infected FLK or SF-28 cells fixed with 3% glutaraldehyde [178].
- ovine virus non-producing NP2 cells synthesizing only the env gene products (gp51 and gp30) and the capsid protein (p24) of BLV [179,180].
Although some of these trials led to partial protection, this strategy has the intrinsic risk of transmitting infection. Therefore, viral subunits were tested for prophylactic immunization.

4.5.3. Viral Subunit Vaccines

First subunit vaccines were designed with the gp51 surface envelope glycoprotein [178,181–184]. The gp51 sequence is indeed well conserved among BLV isolates [91,185–196] and carries at least three neutralizing epitopes [185,197–203].

A subunit vaccine including purified gp51 obtained from culture supernatant of FLK cells inactivated with 0.01% N-acetyleniminme was immunogenic but did not consistently protect from BLV challenge [178]. Native viral gp51 glycoprotein obtained from FLK cell culture supernatant absorbed in Al(OH)$_3$ also failed to prevent BLV infection in calves [182]. A similar unsuccessful attempt was undertaken with the p24 protein [178].

Based on the ability of anti-BLV antibodies in the colostrum to prevent infection, the three aforementioned conventional approaches were focused on inducing an optimal humoral response [33,39,41,98,99,204–207]. Further experimental evidence supporting the role of the humoral response was obtained by successful immunization of naïve sheep with immunoglobulin G from BLV-infected sheep [208]. It should be emphasized that these early vaccination trials included only few animals and were performed over short periods of time. More importantly, the main concern of these experiments was to determine the correct challenge dose encountered under real herd conditions. On the other hand, a major problem of these vaccines was the fast decline of protective antibody titers. Therefore, the significance of these vaccination strategies in herd conditions remains questionable.

Although important, the humoral response quickly appeared to be insufficient for achieving full protection against BLV infection [209–211]. Additionally, antibody titers showed fast decline in vaccinated animals, an undesired feature in an effective vaccine. Due to these initial failures in vaccination against BLV, more emphasis was given on the cellular component of the immune response.

4.5.4. Recombinant Vaccinia Virus

Recombinant vaccinia virus (RVV) was used as a vehicle for immunization against BLV antigens. RVV is a live recombinant vector having a broad host range specificity, the capacity to carry a large amount of genetic information and, most importantly, the ability to elicit both humoral and cell-mediated immunity.

Preliminary studies with RVV coding for gp51 alone induced neither a humoral response nor protected against BLV in sheep or rabbits [209,212]. In contrast, RVV harboring the complete env gene (RVV-env) which encodes both gp51 and gp30 glycoproteins produced a neutralizing humoral response in rabbits and sheep [209,210,212–216]. In one study, RVV-env failed to induce detectable neutralizing specific antibodies and conferred only partial protection in naïve sheep after challenge with BLV [214]. However, the BLV proviral loads were decreased in vaccinated sheep. An efficient immune response correlated with type 1 helper T cell proliferation and delayed hypersensitivity with predominant involvement of CD8 cytotoxic T lymphocytes [214,215,217]. In two other studies, similar RVV-env vaccines induced a strong humoral and CD4+ T cell response and protected against BLV challenge [209,210]. Unfortunately, the RVV-env vaccines were inefficient in cows [211,216–218].
Remarkably, vaccination with RVV-\textit{env} in cattle resulted in increasing titers of IgG1 antibodies which might indicate a type 2 response [218,219]. A RVV vector expressing the \textit{gag}, \textit{pol} and \textit{env} genes also failed to protect cattle after challenge [218].

4.5.5. Synthetic Peptides

Short peptides mimicking gp51 B- and T-cell epitopes were tested as potential immunogens [210,220]. Preliminary analyses with peptides encapsulated in mannan-coated liposomes as delivery system induced significant humoral response and specific Th1 type immunity in mice and sheep models [221–223]. A different cocktail that included multiple synthetic peptides of Th, Tc and B epitopes failed to induce protection after challenge despite a cell-mediated immune response. In the short term, the peptide vaccine partially reduced BLV replication [184]. Finally, a peptide encompassing a minimal 9-mer CTL epitope of gp51 mixed with Freund’s adjuvant induced a cell-mediated response but did not protect most vaccinated sheep against infection [224,225].

Synthetic peptide-based vaccines showed poor performance possibly due to inadequate stereochemical structure and partial epitope presentation.

4.5.6. DNA Vaccines

DNA vaccines can induce a long-lasting immunity engaging both humoral and cellular components of the immune responses.

A DNA vaccine containing the \textit{env} gene under the control of the cytomegalovirus promoter did not induce a vigorous antibody response but stimulated cellular mediated immunity in vaccinated calves. Partial protection was achieved after BLV challenge [226].

Another DNA vaccine was designed to express the Tax transactivator protein. The Tax vector suppressed BLV replication in immunized sheep likely through a Th1-cell response involving CTL activity [227,228]. However, a more recent study showed that a Tax DNA vaccine elicited a cytotoxic response in the early phase of infection but did not prevent later infection [229]. Neither Tax-specific cytotoxic responses nor the proviral loads were predictive of disease outcome.

As other previously developed immunogens, DNA vaccines were thus disappointing.

4.6. Competitive Infection by Attenuated Proviruses

Failure of “traditional vaccines” was likely due to inadequate or short-lived stimulation of all immunity components. Ideally, the optimal vaccine would therefore contain a large number of viral factors permanently stimulating the immune response. Attenuated derivatives of BLV proviruses meet these requirements [169,170,230–237].

Replication-competent BLV proviruses lacking accessory genes and \textit{cis}-acting LTR sequences were designed and evaluated in rats and rabbits [230,231]. A first generation of these genetically simpler viruses was constructed by co-injection of independent vectors encoding \textit{gag-pol} and \textit{env} genes. These constructs were devoid of \textit{tax}, \textit{rex}, \textit{R3} and \textit{G4} and contained promoter \textit{cis}-acting regulatory sequences of spleen necrosis virus (SNV). These BLV simpler hybrid derivatives were infectious and induced specific antibodies in a rat model [230,231]. A second type of virus contained \textit{gag}, \textit{pol} and \textit{env} genes
in a single genome under the control of SNV regulatory sequences. This viral vector was competent for replication and induced antibody responses against \textit{gag} and \textit{env} structural proteins in rats and rabbits [231,232,235]. While PVL were decreased, the viral vector induced protection against viral challenge in a rabbit model.

Another approach to design attenuated BLV viruses was to delete genes dispensable for infectivity but required for efficient replication [169]. Using an infectious molecular clone [150], a series of BLV mutant or deletant proviruses were engineered and evaluated for infectivity, replication and pathogenicity in sheep. As predicted, large deletions in the structural genes (\textit{gag}, \textit{pol}, and \textit{env}) abrogated infectivity [169,238]. Other specific mutations within the genome (the capsid major homology region, the catalytic sites of the integrase) were deleterious [169,170]. A mutation (nucleotide coordinate 6073) of the immunoreceptor tyrosine-based activation (ITAM) motifs localized in the cytoplasmic tail of the transmembrane gp30 glycoprotein impaired replication but not infectivity. Importantly, the pathogenic potential of the 6073-mutated provirus was significantly reduced but the anti-viral humoral response was preserved [170,233,234,237,239].

Other attenuated BLV proviruses were obtained by deletion of the region expanding from the end of the \textit{env} gene to the splice acceptor site of the \textit{tax/rex} mRNA [169]. These mutants lacking R3 and G4 sequences were infectious but replicated at extremely low levels [240]. Similar conclusions were drawn from HTLV mutant proviruses deleted in the ORFs encoding the p12\textsuperscript{I} and p13\textsuperscript{II}/p30\textsuperscript{II} orthologs of R3 and G4 [241–243]. The BLV R3+G4 deletant (pBLVDX) elicited a wild type humoral response but was only very rarely pathogenic in sheep, with a single exception among 20 sheep observed after an unusually long period of latency (7 years) [237].

To summarize, two types of BLV mutants (pBLV6073 and pBLVDX) were infectious, replicated at low levels but elicited a wild-type like immune response. Importantly, these attenuated viruses conferred long-term protection after challenge with a wild-type strain in sheep and partly in cattle [233,234]. Indeed, the idea is that these deleted viruses persistently infect cows and interfere with wild-type BLV propagation in herds. The number of BLV-positive cells is also expected to be reduced in the milk of vaccinated cows, impairing the efficiency of BLV transmission to calves. However, calves born from vaccinated cows with these attenuated mutants would be protected through passive immunization. Whether the attenuated strain is transmitted from cow to calf is presently unknown.

Since attenuated viruses can sometimes be pathogenic, an important issue of these vaccines is biosafety. Pathogenicity can be reduced by combining multiple mutations and deletions that do not affect infectivity but reduce replication. Another risk is conversion of the attenuated vaccine to wild-type. Conceptually, this conversion would only be possible by recombination with another BLV strain. Since the very large majority of the cattle are infected in endemic areas (see Section 3. Epidemiology), the risk is that a fraction of vaccinated animals would become infected with a wild-type virus, a process that occurs anyway with high frequencies. It should also be emphasized that virus recombinations were not observed with attenuated strains even under enforced conditions [233,234].

Trials are currently ongoing to evaluate efficacy and safety of this competitive infection strategy in real herd conditions.
5. BLV as a Model for HTLV Therapy and Prevention

BLV and HTLV-1 are closely related deltaretroviruses sharing a similar genomic organization [14,244–246]. Although HTLV and BLV infect different target cells (T and B lymphocytes, respectively) and induce distinct hematological disorders, the two viruses persist, spread and transform through similar mechanisms. A shared feature of their replication strategy is transcriptional silencing, a process that allows escape from the host immune response [147,150,152,153,247]. Both viruses replicate by colonizing new lymphocytes (infectious cycle) as well as by mitosis of the host cell (clonal expansion) [248–250]. A major driving force of viral spread is delivered by the Tax oncoprotein that continuously stimulates proliferation of the infected cell [246,251,252].

In a perspective of comparative virology, the BLV system is a model of pathogenesis for HTLV [170,253–257] (see Table 2). Important outcomes are outlined in this section.

Table 2. Present and future prevention and treatment strategies for BLV and HTLV-1.

|                          | BOVINE LEUKEMIA VIRUS (BLV) | HUMAN T-CELL LEUKEMIA VIRUS (HTLV-1) |
|--------------------------|-----------------------------|-------------------------------------|
| **PREVENTIVE MEASURES**  |                             |                                     |
| Avoid or minimize viral transmission through infected-cells present in blood, secretions or excretions | - Use disposable material and individual single-use of needles and syringes | - Refrain from sharing needles or syringes with anyone |
|                          |                             | - Clean, disinfect or sterilize non-disposable reusable materials, equipment and surgical instruments during dehorning, tattooing, implanting, cauterizing, castration or ear-tagging procedures | - Avoid donating blood, tissues or organs |
|                          |                             | - Consider natural and/or artificial insemination and embryo transfer with BLV-free donors | - Take precautions to prevent sexual transmission |
|                          |                             | - Feed calves with colostrum or whole milk from non-infected dams | - Refrain from breast-feeding |
|                          |                             | - Use milk replacer or pasteurized colostrum | - Consider short-term breastfeeding (less than 6 months) |
|                          |                             |                                     | - Inactivate virus by heating or freeze/thaw procedures |
| **VACCINATION**          | Not available               | Not available                       |
| **SELECTION**            | Not efficient               | Not applicable                      |
| **COMPETITIVE INFECTION**| Currently tested            | Not applicable                      |
| **TREATMENT**            | VPA but not cost-efficient  | AZT+IFN in acute ATL                |
|                          |                             | AZT+IFN+VPA in acute ATL and lymphoma? |
|                          |                             | AZT+VPA in HAM/TSP?                 |
5.1. Prevention

In the absence of an effective vaccine, control of HTLV-1 infection relies on prevention practices aiming to reduce viral transmission [258].

5.1.1. Interruption or Short-Term Breast-Feeding

Vertical transmission via postnatal breast-feeding is considered as the most clinically relevant route for HTLV-1 transmission, particularly when practiced over long periods [259–262]. Cell-associated but not free virus in breast milk appears to be the source of infection [263, 264]. Consistently, the main preventive measure to decrease the risk of mother to child transmission would be to avoid breast feeding. However, this measure is not always easy to adopt due to behavioral, social and societal reasons. For example, refraining from breast-feeding can lead to social stigma or discrimination and explain why women might have difficulties to follow this recommendation. Furthermore, when sanitary conditions are not met, it might be hazardous to use reconstituted milk with contaminated water. Malnutrition being a primary cause of infant death, poverty can also hamper the use of artificial milk. Finally, there is no optimal substitute for natural milk that provides passive immunity, as described earlier for BLV. Therefore, whilst avoiding or limiting breast-feeding is an effective preventive measure in developed countries where safer alternatives exist, it is frequently not adequate for other regions.

Other strategies also used for BLV include:

- limit the duration of breast feeding (to less than 6 months) [265–267].
- inactivate the virus by heating or freezing-thawing [268–270].

Besides milk, pre- and perinatal infection with HTLV-1 occurs less frequently through transfer of cord blood and placenta syncytiotrofoblastic cells [261, 271]. When the PVLs are high, HTLV-1 transmission could be impaired with anti-retroviral drugs such as AZT.

5.1.2. Prevention of Sexual Transmission

Sexual intercourse is another route of HTLV-1 transmission that occurs more efficiently from men to women [272–275]. As for HIV, the use of condoms is the optimal measure preventing HTLV-1 transmission [258].

5.1.3. Prevention of Iatrogenic Transmission

Although less frequent, iatrogenic transmission of HTLV-1 occurs with low efficacy due to needle sharing by intravenous drug users [276–278]. In fact, HTLV-2 appears to be more prevalent in this group [279–282]. Therefore, individuals are strongly recommended to refrain from sharing needles or syringes [258, 283]. Iatrogenic transmission of HTLV-1 also occurs in organ transplanted recipients and long-term hemodialyzed patients [284–289].

Parenteral infection by transfusion of contaminated blood is a potential threat for HTLV-1 transmission. Rates of 5–6% infection were found among blood donors of highly endemic areas, such as the Caribbean Islands and Japan [290–292]. In medium prevalence areas of South America, these
rates are close to 2% [293–299]. Systematic screening for HTLV-1 in blood banks has become compulsory in many countries. Rapid implementation measures were adopted in highly endemic areas like Japan (1986), Brazil (1993), the Caribbean and the French Isles (1989), as well as in many other developed countries despite low seroprevalence rates (France, USA, Canada, Australia, Netherlands or Denmark). Later on, blood bank screening was applied in developing countries with medium to high seroprevalence among blood donors (Argentina: 2004, Peru: 1999). This policy proved to be successful to decrease HTLV-1 spread by blood transfusion [300–304]. Unfortunately, official screening programs still lack in other regions with high prevalence (Middle East) [305,306], further reflecting differences between industrialized and developing countries.

5.2. Vaccination Strategies

Vaccination is probably the best strategy against HTLV-1 infection particularly in endemic areas with high prevalence and in developing economies where other control measures are not implemented [307]. Unfortunately, an efficient, safe and cost-effective vaccine is not available.

As for BLV, an efficient HTLV-1 vaccine should elicit both humoral response and cell-mediated immunity [308]. Focus was also given to the envelope glycoproteins (gp46 and gp21) and the Tax transactivator. Attempts included:

- heat-inactivated HTLV-1 [309];
- env glycoproteins produced in *Escherichia coli* [310];
- DNA vaccines encoding *tax* or *env* genes (in combination with RVV-env or RVV-env+gag) [311,312];
- synthetic peptide derived from env gp46 [309,313,314] and Tax [315–319];
- complex chimeric synthetic multivalent peptide vaccines [320–323];
- recombinant vaccinia viruses expressing gag and/or env proteins [312,324–329].

Despite interesting preliminary data, none of these vaccines achieved final development mainly due to partial or short-lived response, safety concerns and perhaps also a lack of interest from an industrial partner. No matter the reasons, a vaccine for HTLV or BLV is currently unavailable and will clearly require significant further development.

5.3. Epigenetic Modulation Strategy and Gene Activation Therapy

In the absence of satisfactory therapy and based on preclinical trials performed in animal models [159,167], gene activation therapy is an option to improve treatment of HTLV-infected patients. As previously described for BLV (see Section 3.4), this approach is designed to activate viral gene expression with VPA in order to expose virus-positive cells to the host immune response [159,256].

In primary cells freshly isolated from HAM/TSP patients, VPA induced hyperacetylation, triggered viral expression and was proapoptotic [159,162,163]. Despite early fluctuations, the PVLs were however not significantly affected after two years of VPA treatment [166]. Importantly, VPA did not alter the anti-viral CTL response and generated only minor side effects. Long term treatment with VPA is thus safe but does not alleviate the condition of HAM/TSP. Further attempts to improve treatment are ongoing. Among these, the combination of VPA and AZT can reduce PVL in STLV-1 infected
If applicable to humans, this treatment could be rapidly translated into clinical therapy and reduce the risk of developing HAM/TSP.

For ATL, the standard treatment is currently a combination of AZT and alpha-interferon. This regimen is partly efficient for the acute form but unfortunately inoperant for lymphoma ATL [330,331]. Very recently, an exciting perspective has been presented at the 15th International Conference on Human Retrovirology: VPA combined with AZT and PEG-alpha-interferon induced complete response in 33% of patients associated with molecular remissions (i.e., drop of PVL below threshold levels) [165].

The epigenetic therapy initially developed in the BLV model may thus provide novel opportunities for HTLV-induced diseases.

6. Conclusion

In this review, we outlined the currently available approaches to decrease infection rates of BLV: test and eliminate, segregate or manage (see Table 1). Treatment of BLV leukemia with VPA is not economically sustainable except for animals with high genetic value. In the absence of an efficient vaccine, a new strategy based on competitive infection with deletant viruses is presently being evaluated.

Although aims and ethical rules are different for HTLV and BLV, there is an interesting parallelism in prevention and therapeutic measures (see Table 2). An effective vaccine against these viruses is still desperately lacking. Both systems have benefited from each other leading to a better understanding of the mechanisms of viral persistence and pathogenesis.

Acknowledgments

This work was supported by the “Fonds National de la Recherche Scientifique” (FNRS), the Télévie, the Belgian Foundation against Cancer (FBC), the Sixth Research Framework Programme of the European Union (project INCA LSHC-CT-2005-018704), the “Neoangio” excellence program and the “Partenariat Public Privé” PPP INCA of the “Direction générale des Technologies, de la Recherche et de l’Energie/DG06” of the Walloon government, the “Action de Recherche Concertée Glyvir” (ARC) of the “Communauté française de Belgique”, the “Centre anticancéreux près ULg” (CAC), the “Subside Fédéral de Soutien à la Recherche SYNBIOFOR”, the “ULg Fonds Spéciaux pour la Recherche” and the “Plan Cancer” of the “Service Public Fédéral”. MB, AF, NG, SR (FNRS postdoctoral researchers), FB (Télévie doctoral fellow) and LW (Research Director) are members of the FNRS. AdB is ARC doctoral fellow and MTSA is FBC postdoctoral researcher. This work was supported by Centro de Investigaciones en Ciencias Veterinarias y Agronómicas, INTA, project 421 PNLEC 1602 and Fundación ArgenINTA. G.G. is supported by a fellowship from Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET).

Conflict of Interest

The authors declare having no conflict of interest.
References and Notes

1. Leisering, A. Hypertrophy der Malpighischen Körperchen der Milz. Berl. Vet. West. Kgr. Sachsen 1871, 16, 15–16.
2. Olson, C.; Miller, J. History and terminology of enzootic bovine leukosis. In *Enzootic Bovine Leukosis and Bovine Leukemia Virus*; Burny, A., Mammerickx, M., Eds.; Martinus Nijhoff Publishing: Boston, MA, USA, 1987; pp. 3–14.
3. Bollinger, O. Über Leukämie bei den Haustieren. *Virchows Arch.* 1874, 59, 341–349.
4. Siedamgrotzky, O.; Hofmeister, V. *Anleitung zur mikroskopischen und chemischen Diagnostik der Krankheiten der Haustiere: für Thierärzte und Landwirthe/bearb.* Schönfeld VIII: Dresden, Germany, 1876; p. 192.
5. Schöttler, F.; Schöttler, H. Über Ätiologie und Therapie der Aleukämischen Lymphadenose des Rindes. *Berl. Muench. Tierarztl. Wochenschr.* 1934, 50, 497–502, 513–517.
6. Johnson, R.; Kaneene, J.B. Bovine leukaemia virus and enzootic bovine leukosis. *Vet. Bull.* 1992, 62, 287–312.
7. Bendixen, H.J. Bovine enzootic leukosis. *Adv. Vet. Sci.* 1965, 10, 129–204.
8. Miller, J.M.; Miller, L.D.; Olson, C.; Gillette, K.G. Virus-like particles in phytohemagglutinin-stimulated lymphocyte cultures with reference to bovine lymphosarcoma. *J. Natl. Cancer Inst.* 1969, 43, 1297–1305.
9. Ferrer, J.F.; Marshak, R.R.; Abt, D.A.; Kenyon, S.J. Persistent lymphocytosis in cattle: Its cause, nature and relation to lymphosarcoma. *Ann. Rech. Vet.* 1978, 9, 851–857.
10. Ferrer, J.F. Bovine lymphosarcoma. *Adv. Vet. Sci. Comp. Med.* 1980, 24, 1–68.
11. Burny, A.; Bex, F.; Chantrenne, H.; Cleuter, Y.; Dekegel, D.; Ghysdael, J.; Kettmann, R.; Leclercq, M.; Leunen, J.; Mammerickx, M.; *et al.* Bovine leukemia virus involvement in enzootic bovine leukosis. *Adv. Cancer Res.* 1978, 28, 251–311.
12. Burny, A.; Bruck, C.; Chantrenne, H.; Cleuter, Y.; Dekegel, D.; Ghysdael, J.; Kettmann, R.; Leclercq, M.; Leunen, J.; Mammerickx, M.; *et al.* Bovine leukemia virus: Molecular biology and epidemiology. In *Viral Oncology*; Klein, G., Ed.; Raven Press: New York, NY, USA, 1980.
13. Burny, A.; Bruck, C.; Cleuter, Y.; Couez, D.; Deschamps, J.; Gregoire, D.; Ghysdael, J.; Kettmann, R.; Mammerickx, M.; Marbaix, G.; *et al.* Bovine leukaemia virus and enzootic bovine leukosis. *Onderstepoort J. Vet. Res.* 1985, 52, 133–144.
14. Burny, A.; Cleuter, Y.; Kettmann, R.; Mammerickx, M.; Marbaix, G.; Portetelle, D.; van den Broeke, A.; Willems, L.; Thomas, R. Bovine leukaemia: Facts and hypotheses derived from the study of an infectious cancer. *Vet. Microbiol.* 1988, 17, 197–218.
15. Kettmann, R.; Portetelle, D.; Mammerickx, M.; Cleuter, Y.; Dekegel, D.; Galoux, M.; Ghysdael, J.; Burny, A.; Chantrenne, H. Bovine leukemia virus: An exogenous RNA oncogenic virus. *Proc. Natl. Acad. Sci. U. S. A.* 1976, 73, 1014–1018.
16. Kettmann, R.; Burny, A. Bovine Leukemia Virus. In *The Retroviridae*; Levy, J.A., Ed.; Plenum Press: New York, NY, USA, 1994; Volume 3, pp. 39–81.
17. Kenyon, S.J.; Piper, C.E. Cellular basis of persistent lymphocytosis in cattle infected with bovine leukemia virus. *Infect. Immun.* 1977, 16, 891–897.
18. Ferrer, J.F.; Marshak, R.R.; Abt, D.A.; Kenyon, S.J. Relationship between lymphosarcoma and persistent lymphocytosis in cattle: A review. *J. Am. Vet. Med. Assoc.* **1979**, *175*, 705–708.
19. Schwartz, I.; Levy, D. Pathobiology of bovine leukemia virus. *Vet. Res.* **1994**, *25*, 521–536.
20. Kettmann, R.; Burny, A.; Cleuter, Y.; Ghysdael, J.; Mammerickx, M. Distribution of bovine leukemia virus proviral sequences in tissues of bovine, ovine and human origin. *Ann. Rech. Vet.* **1978**, *9*, 837–844.
21. Kettmann, R.; Meunier-Rotival, M.; Cortadas, J.; Cuny, G.; Ghysdael, J.; Mammerickx, M.; Burny, A.; Bernardi, G. Integration of bovine leukemia virus DNA in the bovine genome. *Proc. Natl. Acad. Sci. U. S. A.* **1979**, *76*, 4822–4826.
22. Kettmann, R.; Meunier-Rotival, M.; Cortadas, J.; Cuny, G.; Ghysdael, J.; Mammerickx, M.; Burny, A.; Bernardi, G. Integration site of bovine leukemia virus DNA in the bovine genome [proceedings]. *Arch. Int. Physiol. Biochim.* **1979**, *87*, 818–819.
23. Kettmann, R.; Cleuter, Y.; Mammerickx, M.; Meunier-Rotival, M.; Bernardi, G.; Burny, A.; Chantrenne, H. Genomic integration of bovine leukemia provirus: Comparison of persistent lymphocytosis with lymph node tumor form of enzootic. *Proc. Natl. Acad. Sci. U. S. A.* **1980**, *77*, 2577–2581.
24. Jacobs, R.M.; Song, Z.; Poon, H.; Heeney, J.L.; Taylor, J.A.; Jefferson, B.; Vernau, W.; Valli, V.E. Proviral detection and serology in bovine leukemia virus-exposed normal cattle and cattle with lymphoma. *Can. J. Vet. Res.* **1992**, *56*, 339–348.
25. Thurmond, M.C. Economics of enzootic bovine leukosis. In *Enzootic bovine leukosis and bovine leukemia virus*; Burny, A., Mammerickx, M., Eds.; Martinus Nijhoff Publishing: Boston, MA, USA, 1987; pp. 71–86.
26. Pelzer, K.D. Economics of bovine leukemia virus infection. *Vet. Clin. North Am. Food Anim. Pract.* **1997**, *13*, 129–141.
27. Trainin, Z.; Brenner, J. The direct and indirect economic impacts of bovine leukemia virus infection on dairy cattle. *Isr. J. Vet. Med.* **2005**, *60*, 90–105.
28. Johnson, R.; Gibson, C.D.; Kaneene, J.B. Bovine leukemia virus: A herd-based control strategy. *Prev. Vet. Med.* **1985**, *3*, 339–349.
29. Hopkins, S.G.; DiGiacomo, R.F. Natural transmission of bovine leukemia virus in dairy and beef cattle. *Vet. Clin. North Am. Food Anim. Pract.* **1997**, *13*, 107–128.
30. Ohshima, K.; Okada, K.; Numakunai, S.; Yoneyama, Y.; Sato, S.; Takahashi, K. Evidence on horizontal transmission of bovine leukemia virus due to blood-sucking tabanid flies. *Nippon Juigaku Zasshi.* **1981**, *43*, 79–81.
31. Perino, L.J.; Wright, R.E.; Hoppe, K.L.; Fulton, R.W. Bovine leukosis virus transmission with mouthparts from Tabanus abactor after interrupted feeding. *Am. J. Vet. Res.* **1990**, *51*, 1167–1169.
32. Ferrer, J.F.; Piper, C.E.; Abt, D.A.; Marshak, R.R.; Bhatt, D.M. Natural mode of transmission of the bovine C type leukemia virus (BLV). *Bibl. Haematol.* **1975**, *43*, 235–237.
33. Lassauzet, M.L.; Thurmond, M.C.; Johnson, W.O.; Holmberg, C.A. Factors associated with in utero or periparturient transmission of bovine leukemia virus in calves on a California dairy. *Can. J. Vet. Res.* **1991**, *55*, 264–268.
34. Piper, C.E.; Ferrer, J.F.; Abt, D.A.; Marshak, R.R. Postnatal and prenatal transmission of the bovine leukemia virus under natural conditions. *J. Natl. Cancer Inst.* **1979**, *62*, 165–168.
35. Agresti, A.; Ponti, W.; Rocchi, M.; Meneveri, R.; Marozzi, A.; Cavalleri, D.; Peri, E.; Poli, G.; Ginelli, E. Use of polymerase chain reaction to diagnose bovine leukemia virus infection in calves at birth. *Am. J. Vet. Res.* **1993**, *54*, 373–378.

36. Ferrer, J.F.; Piper, C.E. Role of colostrum and milk in the natural transmission of the bovine leukemia virus. *Cancer Res.* **1981**, *41*, 4906–4909.

37. Ferrer, J.F.; Piper, C.E. An evaluation of the role of milk in the natural transmission of BLV. *Ann. Rech. Vet.* **1978**, *9*, 803–807.

38. Ferrer, J.F.; Kenyon, S.J.; Gupta, P. Milk of dairy cows frequently contains a leukemogenic virus. *Science* **1981**, *213*, 1014–1016.

39. Van Der Maaten, M.J.; Miller, J.M.; Schmerr, M.J. Effect of colostral antibody on bovine leukemia virus infection of neonatal calves. *Am. J. Vet. Res.* **1981**, *42*, 1498–1500.

40. Van der Maaten, M.J.; Miller, J.M. Susceptibility of cattle to bovine leukemia virus infection by various routes of exposure. In *Advances in Comparative Leukemia Research*; Bentvelzen, P., Hilgers, J., Yohn, D.S., Eds.; Elsevier/North Holland Biomedical Press: Amsterdam, the Netherlands, 1978; pp. 29–32.

41. Lassauzet, M.L.; Johnson, W.O.; Thurmond, M.C.; Stevens, F. Protection of colostral antibodies against bovine leukemia virus infection in calves on a California dairy. *Can. J. Vet. Res.* **1989**, *53*, 424–430.

42. Forschner, E.; Bunger, I.; Krause, H.P. Surveillance investigations of brucellosis-, leukemia- and BHV-free cattle herds. ELISA-based bulk milk studies compared to single animal sample studies with traditional test systems. Safety and cost. *Dtsch. Tierarztl. Wochenschr.* **1988**, *95*, 214–218.

43. Knapen, K.; Kerkhofs, P.; Mammerickx, M. Eradication of enzootic bovine leukemia in Belgium: Results of the mass detection on the national cattle population in 1989, 1990 and 1991. *Ann. Med. Vet.* **1993**, *137*, 197–201.

44. Nuotio, L.; Rusanen, H.; Sihvonen, L.; Neuvonen, E. Eradication of enzootic bovine leukemia from Finland. *Prev. Vet. Med.* **2003**, *59*, 43–49.

45. Acate, J.; Tamosiunas, V.; Lukauskas, K.; Milius, J.; Pieskus, J. The eradication experience of enzootic bovine leukemia virus from Lithuania. *Prev. Vet. Med.* **2007**, *82*, 83–89.

46. OIE World Animal Health Information Database (WAHID Interface), Version 1.4. Available online: http://web.oie.int/wahis/public.php?page=disease_status_detail (accessed on 27 April 2011).

47. NAHIS-AHA Enzootic Bovine Leukosis. Available online: http://www.animalhealthaustralia.com.au/nahis/pmwiki/pmwiki.php?n=Factsheet.90-1 (accessed on 27 April 2011).

48. Hayes, D.; Burton, L. Enzootic bovine leucosis eradication scheme. *Surveillance* **1998**, *25*, 3–5.

49. NAHMS-USDA Bovine Leukosis Virus on U.S. Dairy Operations, 2007. Available online: http://www.aphis.usda.gov/animal_health/nahms/dairy/downloads/dairy07/Dairy07_is_BLV.pdf (accessed on 27 April 2011).

50. Jacobs, R.M.; Pollari, F.L.; McNab, W.B.; Jefferson, B. A serological survey of bovine syncytial virus in Ontario: associations with bovine leukemia and immunodeficiency-like viruses, production records, and management practices. *Can. J. Vet. Res.* **1995**, *59*, 271–278.

51. Van Leeuwen, J.A.; Keefe, G.P.; Tremblay, R.; Power, C.; Wichtel, J.J. Seroprevalence of infection with Mycobacterium avium subspecies paratuberculosis, bovine leukemia virus, and bovine viral diarrhea virus in maritime Canada dairy cattle. *Can. Vet. J.* **2001**, *42*, 193–198.
52. Van Leeuwen, J.A.; Forsythe, L.; Tiwari, A.; Chartier, R. Seroprevalence of antibodies against bovine leukemia virus, bovine viral diarrhea virus, Mycobacterium avium subspecies paratuberculosis, and Neospora caninum in dairy cattle in Saskatchewan. Can. Vet. J. 2005, 46, 56–58.
53. Van Leeuwen, J.A.; Tiwari, A.; Plaizier, J.C.; Whiting, T.L. Seroprevalence of antibodies against bovine leukemia virus, bovine viral diarrhea virus, Mycobacterium avium subspecies paratuberculosis, and Neospora caninum in beef and dairy cattle in Manitoba. Can. Vet. J. 2006, 47, 783–786.
54. Scott, H.M.; Sorensen, O.; Wu, J.T.; Chow, E.Y.; Manninen, K.; Van Leeuwen, J.A., Seroprevalence of Mycobacterium avium subspecies paratuberculosis, Neospora caninum, Bovine leukemia virus, and Bovine viral diarrhea virus infection among dairy cattle and herds in Alberta and agroecological risk factors associated with seropositivity. Can. Vet. J. 2006, 47, 981–991.
55. Marin, C.; de López, N.M.; Álvarez, L.; Lozano, O.; España, W.; Castaños, H.; León, A. Epidemiology of bovine leukemia in Venezuela. Ann. Rech. Vet. 1978, 9, 743–746.
56. Islas, L.A.; Inchaurtieta, S.C.; Muñoz, P.G. Prevalencia de leucosis enzoótica bovina (LEB) en lecherías de las comunas de San Fernando, Chimbarongo y Placilla. Monograf. Med. Vet. 1990, 12, 64–70.
57. Alfonso, R.; Almansa, J.E.; Barrera, J.C. Serological prevalence and evaluation of the risk factors of bovine enzootic leukosis in the Bogota savannah and the Ubate and Chiquinquira Valleys, Colombia. Rev. Sci. Tech. 1998, 17, 723–732.
58. Rama, G.; Moratorio, G.; Greif, G.; Obal, G.; Bianchi, S.; Tomé, L.; Carrion, F.; Meikle, A.; Pritsch, O. Development of a real time PCR assay using SYBR Green chemistry for bovine leukemia virus detection. Retrovirology 2011, 8, A17.
59. Trono, K.G.; Perez-Filgueira, D.M.; Duffy, S.; Borca, M.V.; Carrillo, C. Seroprevalence of bovine leukemia virus in dairy cattle in Argentina: Comparison of sensitivity and specificity of different detection methods. Vet. Microbiol. 2001, 83, 235–248.
60. D'Angelino, J.L.; Garcia, M.; Birgel, E.H. Epidemiological study of enzootic bovine leukosis in Brazil. Trop. Anim. Health Prod. 1998, 30, 13–15.
61. Abreu, V.L.V.; Silva, J.A.; Modena, C.M.; Moreira, É.C.; Figueiredo, M.M.N. Prevalência da leucose enzoótica bovina nos estados de Rondônia e Acre. Arq. Bras. Med. Vet. Zootec. 1990, 42, 203–210.
62. Melo, L.E.H. Leucose enzoótica dos bovinos. Prevalência da infecção em rebanhos leiteiros criados no agreste meridional do estado de Pernambuco. Dissertação (Mestrado), Faculdade de Medicina Veterinária e Zootecnia, Universidade de São Paulo, Sao Paulo, Brazil, 1991; p. 102.
63. Melo, C.B.; Oliveira, A.M.; Figueiredo, H.C.P.; Leite, R.C.; Lobato, Z.I.P. Prevalência de anticorpos contra Herpesvírus Bovino-1, vírus da Diarréia Bovina e Vírus e vírus da Leucose Enzoótica Bovina em bovinos do Estado de Sergipe, Brasil. Rev. Bras. Reprod. Anim. 1997, 21, 160–161.
64. Molnár, E.; Molnár, L.; Tavares Dias, H.; da Silva, A.O.A.; Gomes Vale, W. Ocorrência da Leucose Enzoótica dos Bovinos no Estado do Pará, Brasil. Pesq. Vet. Bras. 1999, 19, 7–11.
65. Leuzzi Junior, L.Á.; Fernandes Alfieri, A.; Alfieri, A.A. Leucose enzoótica bovina e vírus da leucemia bovina. Semina 2001, 22, 211–221.
66. Cerqueira-Leite, R.; Portela Lobato, Z.I.; Fernandes Camargos, M. Leucose Enzoótica Bovina. *Revista CFMFVZ* 2001, 24, 20–28.

67. Del Fava, C.; Pituco, E.M. Infecção pelo vírus da leucemia bovina (BLV) no Brasil. *Biológico* 2004, 66, 1–8.

68. Wang, C.T. Bovine leukemia virus infection in Taiwan: Epizdemiological study. *J. Vet. Med. Sci.* 1991, 53, 395–398.

69. Meas, S.; Ohashi, K.; Tum, S.; Chhin, M.; Te, K.; Miura, K.; Sugimoto, C.; Onuma, M. Seroprevalence of bovine immunodeficiency virus and bovine leukemia virus in draught animals in Cambodia. *J. Vet. Med. Sci.* 2000, 62, 779–781.

70. Murakami, K.; Kobayashi, S.; Konishi, M.; Kameyama, K.; Yamamoto, T.; Tsutsui, T. The recent prevalence of bovine leukemia virus (BLV) infection among Japanese cattle. *Vet. Microbiol.* 2011, 148, 84–88.

71. Suh, G.H.; Lee, J.C.; Lee, C.Y.; Hur, T.Y.; Son, D.S.; Ahn, B.S.; Kim, N.C.; Lee, C.G. Establishment of a bovine leukemia virus-free dairy herd in Korea. *J. Vet. Sci.* 2005, 6, 227–230.

72. Hafez, S.M.; Sharif, M.; Al-Sukayran, A.; Dela-Cruz, D. Preliminary studies on enzootic bovine leukosis in Saudi dairy farms. *Disch. Tierarztl. Wochenschr.* 1990, 97, 61–63.

73. Meas, S.; Seto, J.; Sugimoto, C.; Bakhsh, M.; Riaz, M.; Sato, T.; Naeem, K.; Ohashi, K.; Onuma, M. Infection of Bovine Immunodeficiency Virus and Bovine Leukemia Virus in Water Buffalo and Cattle Populations in Pakistan. *J. Vet. Med. Sci.* 2000, 62, 329–331.

74. Pourjafar, M.; Mahzonieh, M.R.; Heidari Borujeni, M. Serological study of bovine viral leukosis in Borujen, Lordegan and Farsan. In Proceedings of the 23rd World Buiatrics Congress, Quebec City, Canada, 11–16 July 2004; p. 338.

75. Burgu, I.; Alkan, F.; Karamghi, T.; Bilge-Dagalp, S.; Can-Sahna, K.; Gunor, B.; Demir, B. Control and eradication programme of enzootic bovine leucosis (EBL) from selected dairy herds in Turkey. *Disch. Tierarztl. Wochenschr.* 2005, 112, 271–274.

76. Haghparast, A.; Mohammadi, G.; Mousavi, S. Seroepidemiology of bovine leukemia virus (BLV) infection in the north eastern provinces of Iran. In Proceedings of the XVI Congress of the Mediterranean Federation for Health and Production of Ruminants, Zadar, Croatia, 22–26 April 2008; Harapin, I., Kos, J., Eds.; Faculty of Veterinary medicine, Zagreb Croatian Veterinary Chamber: Zadar, Croatia, 2008; p. 504.

77. Bruijeni, G.N.; Poorbazargani, T.T.; Nadin-Davis, S.; Tolooie, M.; Barjesteh, N. Bovine immunodeficiency virus and bovine leukemia virus and their mixed infection in Iranian Holstein cattle. *J. Infect. Dev. Ctries.* 2010, 4, 576–579.

78. Tan, M.T.; Yildirim, Y.; Erol, N.; Gunor, A.B. The seroprevalence of bovine herpes virus type 1 (BHV-1) and bovine leukemia virus (BLV) in selected dairy cattle herds in Aydin province, Turkey. *Turk. J. Vet. Anim. Sci.* 2006, 30, 353–357.

79. Ferrer, J.F. Bovine leukosis: Natural transmission and principles of control. *J. Am. Vet. Med. Assoc.* 1979, 175, 1281–1286.

80. DiGiacomo, R.F. The epidemiology and control of bovine leukemia virus infection. *Vet. Med.* 1992, 87, 248–257.
81. Mamerickx, M.; Cormann, A.; Burny, A.; Dekegel, D.; Portetelle, D. Eradication of enzootic bovine leukosis based on the detection of the disease by the GP immunodiffusion test. *Ann. Rech. Vet.* **1978**, *9*, 885–894.

82. Straub, O.C. First results of a new sanitation program concerning the eradication of enzootic bovine leukosis. *Ann. Rech. Vet.* **1978**, *9*, 895–898.

83. Maas-Inderwiesen, F.; Albrecht, A.; Bause, I.; Osmers, M.; Schmidt, F.W. Effect of leukemia control on the development of enzootic bovine leukosis in Lower Saxony. *Dtsch. Tierarztl. Wochenschr.* **1978**, *85*, 309–313.

84. Van Der Maaten, M.J.; Miller, J.M. Appraisal of control measures for bovine leukemia. *J. Am. Vet. Med. Assoc.* **1979**, *175*, 1287–1290.

85. Roberts, D.H.; Bushnell, S. Herd eradication of enzootic bovine leukemia. *Vet. Rec.* **1982**, *111*, 487.

86. Schmidt, F.W. In *Results and observations of an EBL eradication programme based on AGIDT diagnosis and culling of reactors*, Proceedings of the Fourth International Symposium on Bovine Leukosis, Bologna, Italy, 5–7 November 1980; Straub, O.C., Ed.; Martinus Nijhoff Publishing: Dordrecht, The Netherlands, 1982; pp. 491–497.

87. Yoshikawa, T.; Yoshikawa, H.; Koyama, H.; Tsubaki, S. Preliminary attempts to eradicate infection with bovine leukemia virus from a stock farm in Japan. *Nippon Juigaku Zasshi* **1982**, *44*, 831–843.

88. Ohshima, K.; Okada, K.; Numakunai, S.; Kayano, H.; Goto, T. An eradication program without economic loss in a herd infected with bovine leukemia virus (BLV). *Nippon Juigaku Zasshi* **1988**, *50*, 1074–1078.

89. Wang, C.T.; Onuma, M. Attempt to eradicate bovine leukemia virus-infected cattle from herds. *Jpn. J. Vet. Res.* **1992**, *40*, 105–111.

90. Asfaw, Y.; Tsuduku, S.; Konishi, M.; Murakami, K.; Tsuboi, T.; Wu, D.; Sentsui, H. Distribution and superinfection of bovine leukemia virus genotypes in Japan. *Arch. Virol.* **2005**, *150*, 493–505.

91. Monti, G.; Schrijver, R.; Beier, D. Genetic diversity and spread of Bovine leukaemia virus isolates in Argentine dairy cattle. *Arch. Virol.* **2005**, *150*, 443–458.

92. Shettigara, P.T.; Samagh, B.S.; Lobinowich, E.M. Control of bovine leukemia virus infection in dairy herds by agar gel immunodiffusion test and segregation of reactors. *Can. J. Vet. Res.* **1989**, *53*, 108–110.

93. Brenner, J.; Meiron, R.; Avraham, R.; Savir, S.; Trainin, Z. Trial of two methods for the eradication of bovine leucosis virus infection from two large dairy herds in Israel. *Isr. J. Vet. Med.* **1988**, *44*, 168–175.

94. Kaja, R.W.; Olson, C.; Rowe, R.F.; Stauffacher, R.H.; Strozinski, L.L.; Hardie, A.R.; Bause, I. Establishment of a bovine leukosis virus-free dairy herd. *J. Am. Vet. Med. Assoc.* **1984**, *184*, 184–185.

95. Otachel-Hawranek, J. Eradication of enzootic bovine leukosis in dairy cattle from the lower Silesia region. *Bull. Vet. Inst. Pulawy* **2007**, *51*, 465–469.

96. OIE. Enzootic bovine leukemia. In *Manual of Diagnostic Tests and Vaccines for Terrestrial Animals*; World Organisation for Animal Health: Paris, France, 2008; Volume 2, Chapter 2.4.11, pp. 729–738.
97. Evermann, J.F.; DiGiacomo, R.F.; Ferrer, J.F.; Parish, S.M. Transmission of bovine leukosis virus by blood inoculation. *Am. J. Vet. Res.* **1986**, *47*, 1885–1887.

98. Burridge, M.J.; Thurmond, M.C.; Miller, J.M.; Schmerr, M.J.; Van Der Maaten, M.J. Duration of colostral antibodies to bovine leukemia virus by two serologic tests. *Am. J. Vet. Res.* **1982**, *43*, 1866–1867.

99. Burridge, M.J.; Thurmond, M.C.; Miller, J.M.; Schmerr, M.J.; Van Der Maaten, M.J. Fall in antibody titer to bovine leukemia virus in the periparturient period. *Can. J. Comp. Med.* **1982**, *46*, 270–271.

100. Lew, A.E.; Bock, R.E.; Miles, J.; Cuttell, L.B.; Steer, P.; Nadin-Davis, S.A. Sensitive and specific detection of bovine immunodeficiency virus and bovine syncytial virus by 5’ Taq nuclease assays with fluorescent 3’ minor groove binder-DNA probes. *J. Virol. Methods* **2004**, *116*, 1–9.

101. Jimba, M.; Takeshima, S.N.; Matoba, K.; Endoh, D.; Aida, Y. BLV-CoCoMo-qPCR: Quantitation of bovine leukemia virus proviral load using the CoCoMo algorithm. *Retrovirology* **2010**, *7*, 91.

102. Juliarena, M.A.; Gutiérrez, S.E.; Ceriani, C. Determination of proviral load in bovine leukemia virus-infected cattle with and without lymphocytosis. *Am. J. Vet. Res.* **2007**, *68*, 1220–1225.

103. Esteban, E.N.; Poli, M.; Poiesz, B.; Ceriani, C.; Dube, S.; Gutiérrez, S.; Dolcini, G.; Gagliardi, R.; Perez, S.; Lützelschwab, C.; *et al.* Bovine leukemia virus (BLV), proposed control and eradication programs by marker assisted breeding of genetically resistant cattle. In *Animal Genetics*; Rechi, L.J., Eds.; Nova Science Publishers, Inc: Hauppauge, NY, USA, 2009; Chapter 6, pp. 107–130.

104. Gutiérrez, G.; Alvarez, I.; Politzki, R.; Lomónaco, M.; Dus Santos, M.J.; Rondelli, F.; Fondevila, N.; Trono, K. Natural progression of bovine leukemia virus infection in Argentinean dairy cattle. *Vet. Microbiol.* **2011**, in press.

105. Ruppanner, R.; Behymer, D.E.; Paul, S.; Miller, J.M.; Theilen, G.H. A strategy for control of bovine leukemia virus infection: test and corrective management. *Can. Vet. J.* **1983**, *24*, 192–195.

106. Sprecher, D.J.; Pelzer, K.D.; Lessard, P. Possible effect of altered management practices on seroprevalence of bovine leukemia virus in heifers of a dairy herd with history of high prevalence of infection. *J. Am. Vet. Med. Assoc.* **1991**, *199*, 584–588.

107. Bacon, L.D. Influence of the major histocompatibility complex on disease resistance and productivity. *Poult. Sci.* **1987**, *66*, 802–11.

108. Gogolin-Ewens, K.J.; Meeusen, E.N.; Scott, P.C.; Adams, T.E.; Brandon, M.R. Genetic selection for disease resistance and traits of economic importance in animal production. *Rev. Sci. Tech.* **1990**, *9*, 865–896.

109. Warner, C.M.; Meeker, D.L.; Rothschild, M.F. Genetic control of immune responsiveness: A review of its use as a tool for selection for disease resistance. *J. Anim. Sci.* **1987**, *64*, 394–406.

110. Lamont, S.J. Impact of genetics on disease resistance. *Poult. Sci.* **1998**, *77*, 1111–1118.

111. Amorena, B.; Stone, W.H. Serologically defined (SD) locus in cattle. *Science* **1978**, *201*, 159–160.

112. Spooner, R.L.; Leveziel, H.; Grosclaude, F.; Oliver, R.A.; Vaiman, M. Evidence for a possible major histocompatibility complex (BLA) in cattle. *J. Immunogenet.* **1978**, *5*, 325–346.
113. Spooner, R.L.; Oliver, R.A.; Sales, D.I.; McCoubrey, C.M.; Millar, P.; Morgan, A.G.; Amorena, B.; Bailey, E.; Bernoco, D.; Brandon, M.; et al. Analysis of alloantisera against bovine lymphocytes. Joint report of the 1st International Bovine Lymphocyte Antigen (BoLA) workshop. *Anim. Blood Groups Biochem. Genet.* 1979, 10, 63–86.
114. Burridge, M.J.; Wilcox, C.J.; Hennemann, J.M. Influence of genetic factors on the susceptibility of cattle to bovine leukemia virus infection. *Eur. J. Cancer* 1979, 15, 1395–1400.
115. Lewin, H.A.; Bernoco, D. Evidence for BoLA-linked resistance and susceptibility to subclinical progression of bovine leukaemia virus infection. *Anim. Genet.* 1986, 17, 197–207.
116. Stear, M.J.; Dimmock, C.K.; Newman, M.J.; Nicholas, F.W. BoLA antigens are associated with increased frequency of persistent lymphocytosis in bovine leukaemia virus infected cattle and with increased incidence of antibodies to bovine leukaemia virus. *Anim. Genet.* 1988, 19, 151–158.
117. Lewin, H.A.; Wu, M.C.; Stewart, J.A.; Nolan, T.J. Association between BoLA and subclinical bovine leukemia virus infection in a herd of Holstein-Friesian cows. *Immunogenetics* 1988, 27, 338–344.
118. Bull, R.W.; Lewin, H.A.; Wu, M.C.; Peterbaugh, K.; Antczak, D.; Bernoco, D.; Cwik, S.; Dam, L.; Davies, C.; Dawkins, R.L.; et al. Joint report of the Third International Bovine Lymphocyte Antigen (BoLA) Workshop, Helsinki, Finland, 27 July 1986. *Anim. Genet.* 1989, 20, 109–132.
119. Palmer, C.; Thurmond, M.; Picanso, J.; Brewer, A.W.; Bernoco, D. In *Susceptibility of cattle bovine leukemia virus infection associated with BoLA type*, Proceedings of the 91st Annual Meeting of United States Animal Health Association, Salk Lake City, UT, USA, 25–30 October 1987; United States Animal Health Association: Richmond, VA, USA, 1987; pp. 218–228.
120. van Eijk, M.J.; Stewart-Haynes, J.A.; Beever, J.E.; Fernando, R.L.; Lewin, H.A. Development of persistent lymphocytosis in cattle is closely associated with DRB2. *Immunogenetics* 1992, 37, 64–68.
121. Xu, A.; van Eijk, M.J.; Park, C.; Lewin, H.A. Polymorphism in BoLA-DRB3 exon 2 correlates with resistance to persistent lymphocytosis caused by bovine leukemia virus. *J. Immunol.* 1993, 151, 6977–6985.
122. van Eijk, M.J.; Stewart-Haynes, J.A.; Lewin, H.A. Extensive polymorphism of the BoLA-DRB3 gene distinguished by PCR-RFLP. *Anim. Genet.* 1992, 23, 483–496.
123. Burke, M.G.; Stone, R.T.; Muggli-Cockett, N.E. Nucleotide sequence and northern analysis of a bovine major histocompatibility class II DR beta-like cDNA. *Anim. Genet.* 1991, 22, 343–352.
124. Mirsky, M.L.; Olmstead, C.; Da, Y.; Lewin, H.A. Reduced bovine leukaemia virus proviral load in genetically resistant cattle. *Anim. Genet.* 1998, 29, 245–252.
125. Zanotti, M.; Poli, G.; Ponti, W.; Polli, M.; Rocchi, M.; Bolzani, E.; Longeri, M.; Russo, S.; Lewin, H.A.; van Eijk, M.J. Association of BoLA class II haplotypes with subclinical progression of bovine leukaemia virus infection in Holstein-Friesian cattle. *Anim. Genet.* 1996, 27, 337–341.
126. Udina, I.G.; Karamysheva, E.E.; Turkova, S.O.; Orlova, A.R.; Sulimova, G.E. Genetic mechanisms of resistance and susceptibility to leukemia in Ayshire and black pied cattle breeds determined by allelic distribution of gene Bola-DRB3. *Genetika* 2003, 39, 383–396.
127. Juliarena, M.A.; Poli, M.; Sala, L.; Ceriani, C.; Gutierrez, S.; Dolcini, G.; Rodriguez, E.M.; Marino, B.; Rodriguez-Dubra, C.; Esteban, E.N. Association of BLV infection profiles with alleles of the BoLA-DRB3.2 gene. Anim. Genet. 2008, 39, 432–438.
128. Takashima, I.; Olson, C. Histocompatibility antigens in bovine lymphosarcoma. A preliminary study. Ann. Rech. Vet. 1978, 9, 821–823.
129. Aida, Y. Influence of host genetic differences on leukemogenesis induced bovine leukaemia virus. AIDS Res. Hum. Retroviruses 2001, 17, 12.
130. Nagaoka, Y.; Kabeya, H.; Onuma, M.; Kasai, N.; Okada, K.; Aida, Y. Ovine MHC class II DRB1 alleles associated with resistance or susceptibility to development of bovine leukemia virus-induced ovine lymphoma. Cancer Res. 1999, 59, 975–981.
131. Kabeya, H.; Ohashi, K.; Oyunbileg, N.; Nagaoka, Y.; Aida, Y.; Sugimoto, C.; Yokomizo, Y.; Onuma, M. Up-regulation of tumor necrosis factor alpha mRNA is associated with bovine-leukemia virus (BLV) elimination in the early phase of infection. Vet. Immunol. Immunopathol. 1999, 68, 255–265.
132. Konnai, S.; Usui, T.; Ikeda, M.; Kohara, J.; Hirata, T.; Okada, K.; Ohashi, K.; Onuma, M. Tumor necrosis factor-alpha genetic polymorphism may contribute to progression of bovine leukemia virus-infection. Microbes Infect. 2006, 8, 2163–2171.
133. Bojarojc-Nosowicz, B.; Kaczmarczyk, E. Somatic cell count and chemical composition of milk in naturally BLV-infected cows with different phenotypes of blood leukocyte acid phosphatase. Archiv. für Tierzucht. 2006, 49, 17–28.
134. Lewin, H.A. Disease resistance and immune response genes in cattle: Strategies for their detection and evidence of their existence. J. Dairy Sci. 1989, 72, 1334–1348.
135. Lander, E.S.; Schork, N.J. Genetic dissection of complex traits. Science 1994, 265, 2037–2048.
136. Kramnik, I.; Boyartchuk, V. Immunity to intracellular pathogens as a complex genetic trait. Curr. Opin. Microbiol. 2002, 5, 111–117.
137. Glass, E.J.; Baxter, R.; Leach, R.; Taylor, G. Bovine viral diseases: The role of host genetics. In Breeding for Disease Resistance in Farm Animals, 3rd ed.; Bishop, S.C., Axford, R.F.E., Owen, J., Nicholas, F., Eds.; CAB International: Oxfordshire, UK, 2011; Chapter 6, pp. 88–140.
138. Williams, J.L. The use of marker-assisted selection in animal breeding and biotechnology. Rev. Sci. Tech. Off. Int. Epiz. 2005, 24, 379–391.
139. Juliarena, M.A.; Poli, M.; Ceriani, C.; Sala, L.; Rodriguez, E.; Gutierrez, S.; Dolcini, G.; Odeon, A.; Esteban, E.N. Antibody response against three widespread bovine viruses is not impaired in Holstein cattle carrying bovine leukocyte antigen DRB3.2 alleles associated with bovine leukemia virus resistance. J. Dairy Sci. 2009, 92, 375–381.
140. Ng, H.H.; Bird, A. Histone deacetylases: Silencers for hire. Trends Biochem. Sci. 2000, 25, 121–126.
141. Graessle, S.; Loidl, P.; Brosch, G. Histone acetylation: Plants and fungi as model systems for the investigation of histone deacetylases. Cell. Mol. Life Sci. 2001, 58, 704–720.
142. Czermin, B.; Imhof, A. The sounds of silence-histone deacetylation meets histone methylation. Genetica 2003, 117, 159–164.
143. Yoo, C.B.; Jones, P.A. Epigenetic therapy of cancer: Past, present and future. Nat. Rev. Drug Discov. 2006, 5, 37–50.
144. Papait, R.; Monti, E.; Bonapace, I.M. Novel approaches on epigenetics. *Curr. Opin. Drug Discov. Devel.* 2009, 12, 264–275.

145. Wanczyk, M.; Roszczenko, K.; Marcinkiewicz, K.; Bojarczuk, K.; Kowara, M.; Winiarska, M. HDACi-going through the mechanisms. *Front. Biosci.* 2011, 16, 340–359.

146. de Ruijter, A.J.; van Gennip, A.H.; Caron, H.N.; Kemp, S.; van Kuilenburg, A.B. Histone deacetylases (HDACs): Characterization of the classical HDAC family. *Biochem. J.* 2003, 370, 737–749.

147. Kettmann, R.; Marbaix, G.; Cleuter, Y.; Portetelle, D.; Mammerickx, M.; Burny, A. Genomic integration of bovine leukemia provirus and lack of viral RNA expression in the target cells of cattle with different responses to BLV infection. *Leuk. Res.* 1980, 4, 509–519.

148. Gupta, P.; Ferrer, J.F. Expression of bovine leukemia virus genome is blocked by a nonimmunoglobulin protein in plasma from infected cattle. *Science* 1982, 215, 405–407.

149. Kashniri, S.V.; Mehdi, R.; Gupta, P.; Ferrer, J.F. Methylation and expression of bovine leukemia proviral DNA. *Biochem. Biophys. Res. Commun.* 1985, 129, 126–133.

150. Van den Broeke, A.; Cleuter, Y.; Chen, G.; Portetelle, D.; Mammerickx, M.; Zagury, D.; Fouchard, M.; Coulombel, L.; Kettmann, R.; Burny, A. Even transcriptionally competent proviruses are silent in bovine leukemia virus-induced sheep tumor cells. *Proc. Natl. Acad. Sci. U. S. A.* 1988, 85, 9263–3267.

151. Lagarias, D.M.; Radke, K. Transcriptional activation of bovine leukemia virus in blood cells from experimentally infected, asymptomatic sheep with latent infections. *J. Virol.* 1989, 63, 2099–2107.

152. Merimi, M.; Klener, P.; Szynal, M.; Cleuter, Y.; Bagnis, C.; Kerkhofs, P.; Burny, A.; Martiat, P.; Van den Broeke, A. Complete suppression of viral gene expression is associated with the onset and progression of lymphoid malignancy: Observations in Bovine Leukemia Virus-infected sheep. *Retrovirology* 2007, 4, 51.

153. Merimi, M.; Klener, P.; Szynal, M.; Cleuter, Y.; Kerkhofs, P.; Burny, A.; Martiat, P.; Van den Broeke, A. Suppression of viral gene expression in bovine leukemia virus-associated B-cell malignancy: interplay of epigenetic modifications leading to chromatin with a repressive histone code. *J. Virol.* 2007, 81, 5929–5939.

154. Kerkhofs, P.; Adam, E.; Droogmans, L.; Portetelle, D.; Mammerickx, M.; Burny, A.; Kettmann, R.; Willems, L. Cellular pathways involved in the *ex vivo* expression of bovine leukemia virus. *J. Virol.* 1996, 70, 2170–2177.

155. Merezak, C.; Reichert, M.; Van Lint, C.; Kerkhofs, P.; Portetelle, D.; Willems, L.; Kettmann, R. Inhibition of histone deacetylases induces bovine leukemia virus expression *in vitro* and *in vivo*. *J. Virol.* 2002, 76, 5034–5042.

156. Tajima, S.; Tsukamoto, M.; Aida, Y. Latency of viral expression *in vivo* is not related to CpG methylation in the U3 region and part of the R region of the long terminal repeat of bovine leukemia virus. *J. Virol.* 2003, 77, 4423–4430.
157. Calomme, C.; Dekoninck, A.; Nizet, S.; Adam, E.; Nguyen, T.L.; Van Den Broeke, A.; Willems, L.; Kettmann, R.; Burny, A.; Van Lint, C. Overlapping CRE and E box motifs in the enhancer sequences of the bovine leukemia virus 5’ long terminal repeat are critical for basal and acetylation-dependent transcriptional activity of the viral promoter: implications for viral latency. *J. Virol.* **2004**, *78*, 13848–13864.

158. Nguyen, T.L.; Calomme, C.; Wijmeersch, G.; Nizet, S.; Veithen, E.; Portetelle, D.; de Launoit, Y.; Burny, A.; Van Lint, C. Deacetylase inhibitors and the viral transactivator TaxBLV synergistically activate bovine leukemia virus gene expression via a cAMP-responsive element- and cAMP-responsive element-binding protein-dependent mechanism. *J. Biol. Chem.* **2004**, *279*, 35025–35036.

159. Achachi, A.; Florins, A.; Gillet, N.; Debacq, C.; Urbain, P.; Foutsop, G.M.; Vandermeers, F.; Jasik, A.; Reichert, M.; Kerkhofs, P.; et al. Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression *in vivo*. *Proc. Natl. Acad. Sci. U. S. A.* **2005**, *102*, 10309–10314.

160. Pierard, V.; Guiguen, A.; Colin, L.; Wijmeersch, G.; Vanhulle, C.; Van Driessche, B.; Dekoninck, A.; Blazkova, J.; Cardona, C.; Merini, M.; et al. DNA cytosine methylation in the bovine leukemia virus promoter is associated with latency in a lymphoma-derived B-cell line: potential involvement of direct inhibition of cAMP-responsive element (CRE)-binding protein/CRE modulator/activation transcription factor binding. *J. Biol. Chem.* **2010**, *285*, 19434–19449.

161. Merezak, C.; Pierreux, C.; Adam, E.; Lemaigre, F.; Rousseau, G.G.; Calomme, C.; Van Lint, C.; Christophe, D.; Kerkhofs, P.; Burny, A.; et al. Suboptimal enhancer sequences are required for efficient bovine leukemia virus propagation *in vivo*: Implications for viral latency. *J. Virol.* **2001**, *75*, 6977–6988.

162. Gillet, N.; Florins, A.; Boxus, M.; Burteau, C.; Nigro, A.; Vandermeers, F.; Balon, H.; Bouzar, A.B.; Defoiche, J.; Burny, A.; et al. Mechanisms of leukemogenesis induced by bovine leukemia virus: Prospects for novel anti-retroviral therapies in human. *Retrovirology* **2007**, *4*, 18.

163. Lezin, A.; Gillet, N.; Olindo, S.; Signate, A.; Grandvaux, N.; Verlaeten, O.; Belrose, G.; de Carvalho Bittencourt, M.; Hiscott, J.; Asquith, B.; et al. Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients. *Blood* **2007**, *110*, 3722–3728.

164. Bouzar, A.B.; Boxus, M.; Defoiche, J.; Berchem, G.; Macallan, D.; Pettengell, R.; Willis, F.; Burny, A.; Lagneaux, L.; Bron, D.; et al. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. *Br. J. Haematol.* **2009**, *144*, 41–52.

165. Ramos, J.C.; Toomey, N.; Diaz, L.; Ruiz, P.; Barber, G.; Harrington, W., Jr. Targeting HTLV-I latency in Adult T-cell Leukemia/Lymphoma. *Retrovirology* **2011**, *8*, A48.

166. Olindo, S.; Belrose, G.; Gillet, N.; Rodríguez, S.M.; Asquith, B.; Bangham, C.; Signaté, A.; Smadja, D.; Lezin, A.; Césaire, R.; et al. Safety of long-term treatment of HAM/TSP patients with valproic acid. *Blood* 2011, submitted for publication.

167. Afonso, P.V.; Mekaouche, M.; Mortreux, F.; Toulza, F.; Moriceau, A.; Wattel, E.; Gessain, A.; Bangham, C.R.; Dubreuil, G.; Plumelle, Y.; et al. Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors. *Blood* **2010**, *116*, 3802–3808.
168. Willems, L.; Portetelle, D.; Kerkhofs, P.; Chen, G.; Burny, A.; Mammerickx, M.; Kettmann, R. \textit{In vivo} transfection of bovine leukemia provirus into sheep. \textit{Virology} 1992, 189, 775–7.

169. Willems, L.; Kettmann, R.; Dequiedt, F.; Portetelle, D.; Voneche, V.; Cornil, I.; Kerkhofs, P.; Burny, A.; Mammerickx, M. \textit{In vivo} infection of sheep by bovine leukemia virus mutants. \textit{J. Virol.} 1993, 67, 4078–4085.

170. Willems, L.; Burny, A.; Collete, D.; Dangoisse, O.; Dequiedt, F.; Gatot, J.S.; Kerkhofs, P.; Lefebvre, L.; Merezak, C.; Peremans, T.; \textit{et al}. Genetic determinants of bovine leukemia virus pathogenesis. \textit{AIDS Res. Hum. Retroviruses} 2000, 16, 1787–1795.

171. Miller, J.M.; Van Der Maaten, M.J. Evaluation of an inactivated bovine leukemia virus preparation as an immunogen in cattle. \textit{Ann. Rech. Vet.} 1978, 9, 871–877.

172. Patrascu, I.V.; Coman, S.; Sandu, I.; Stiube, P.; Munteanu, I.; Coman, T.; Ionescu, M.; Popescu, D.; Mihailescu, D. Specific protection against bovine leukemia virus infection conferred on cattle by the Romanian inactivated vaccine BL-VACC-RO. \textit{Virologie} 1980, 31, 95–102.

173. Parfanovich, M.I.; Zhdanov, V.M.; Lazarenko, A.A.; Nomm, E.M.; Simovart Yu, A.; Parakin, V.K.; Lemesh, V.M. The possibility of specific protection against bovine leukaemia virus infection and bovine leukaemia with inactivated BLV. \textit{Br. Vet. J.} 1983, 139, 137–146.

174. Miller, J.M.; Van der Maaten, M.J.; Schmerr, M.J. Vaccination of cattle with binary ethylenimine-treated bovine leukemia virus. \textit{Am. J. Vet. Res.} 1983, 44, 64–67.

175. Fukuyama, S.; Kodama, K.; Hirahara, T.; Nakajima, N.; Takamura, K.; Sasaki, O.; Imanishi, J. Protection against bovine leukemia virus infection by use of inactivated vaccines in cattle. \textit{J. Vet. Med. Sci.} 1993, 55, 99–106.

176. Ristau, E.; Beier, D.; Wittmann, W. The course of infection with bovine leukosis virus (BLV) in calves after the administration of cell extract from lymph node tumors of BLV-infected cattle. \textit{Arch. Exp. Veterinarmed.} 1987, 41, 323–331.

177. Ristau, E.; Beier, D.; Wittmann, W.; Klima, F. Protection of sheep against infection with bovine leukemia virus by vaccination with tumor cells or tumor cell preparations from lymph nodes of leukemic cattle. \textit{Arch. Exp. Veterinarmed.} 1987, 41, 185–196.

178. Onuma, M.; Hodatsu, T.; Yamamoto, S.; Higashihara, M.; Masu, S.; Mikami, T.; Izawa, H. Protection by vaccination against bovine leukemia virus infection in sheep. \textit{Am. J. Vet. Res.} 1984, 45, 1212–1215.

179. Altaner, C.; Altanerova, V.; Ban, J.; Janik, V.; Volejnicek, V.; Frajs, Z.; Cerny, L. Cell-derived vaccine against bovine leukaemia virus infection. \textit{Zentralbl. Veterinarmed. B} 1988, 35, 736–746.

180. Altaner, C.; Ban, J.; Altanerova, V.; Janik, V. Protective vaccination against bovine leukaemia virus infection by means of cell-derived vaccine. \textit{Vaccine} 1991, 9, 889–895.

181. Miller, J.M.; Van der Maaten, M.J.; Schmerr, M.J.F. Vaccination with glycosidase-treated glycoprotein antigen does not prevent bovine leukosis virus infection in cattle. In Proceedings of the Fifth International Symposium on Bovine Leukosis, Tubingen, Germany, 19–21 October 1982; Straub, O.C., Ed.; Office for official publications of the European Communities: Luxembourg, 1984.

182. Burkhardt, H.; Rosenthal, S.; Wittmann, W.; Starick, E.; Scholz, D.; Rosenthal, H.A.; Kluge, K.H. Immunization of young cattle with gp51 of the bovine leukosis virus and the subsequent experimental infection. \textit{Arch. Exp. Veterinarmed.} 1989, 43, 933–942.
183. Merza, M.; Sober, J.; Sundquist, B.; Toots, I.; Morein, B. Characterization of purified gp 51 from bovine leukemia virus integrated into iscom. Physicochemical properties and serum antibody response to the integrated gp51. Arch. Virol. 1991, 120, 219–231.

184. Kabeya, H.; Ohashi, K.; Ohishi, K.; Sugimoto, C.; Amanuma, H.; Onuma, M. An effective peptide vaccine to eliminate bovine leukaemia virus (BLV) infected cells in carrier sheep. Vaccine 1996, 14, 1118–1122.

185. Mamoun, R.Z.; Morisson, M.; Rebeyrotte, N.; Busseta, B.; Couez, D.; Kettmann, R.; Hospital, M.; Guillemain, B. Sequence variability of bovine leukemia virus env gene and its relevance to the structure and antigenicity of the glycoproteins. J. Virol. 1990, 64, 4180–4188.

186. Willems, L.; Thienpont, E.; Kerkhofs, P.; Burny, A.; Mammerickx, M.; Kettmann, R. Bovine leukemia virus, an animal model for the study of intrastrain variability. J. Virol. 1993, 67, 1086–1089.

187. Fechner, H.; Blankenstein, P.; Looman, A.C.; Elwert, J.; Geue, L.; Albrecht, C.; Kurg, A.; Beier, D.; Marquardt, O.; Ebner, D. Provirus variants of the bovine leukemia virus and their relation to the serological status of naturally infected cattle. Virology 1997, 237, 261–269.

188. Beier, D.; Blankenstein, P.; Marquardt, O.; Kuzmak, J. Identification of different BLV provirus isolates by PCR, RFLPA and DNA sequencing. Berl. Munch. Tierarztl. Wochenschr. 2001, 114, 252–256.

189. Camargos, M.F.; Pereda, A.; Stancek, D.; Rocha, M.A.; dos Reis, J.K.; Greiser-Wilke, I.; Leite, R.C. Molecular characterization of the env gene from Brazilian field isolates of Bovine leukemia virus. Virus Genes 2007, 34, 343–350.

190. Licursi, M.; Inoshima, Y.; Wu, D.; Yokoyama, T.; González, E.T.; Sentsui, H. Provirus variants of bovine leukemia virus in naturally infected cattle from Argentina and Japan. Vet. Microbiol. 2003, 96, 17–23.

191. Felmer, R.; Munoz, G.; Zuniga, J.; Recabal, M. Molecular analysis of a 444 bp fragment of the bovine leukaemia virus gp51 env gene reveals a high frequency of non-silent point mutations and suggests the presence of two subgroups of BLV in Chile. Vet. Microbiol. 2005, 108, 39–47.

192. Hemmatzadeh, F. Sequencing and phylogenetic analysis of gp51 gene of bovine leukaemia virus in Iranian isolates. Vet. Res. Commun. 2007, 31, 783–789.

193. Zhao, X.; Buehring, G.C. Natural genetic variations in bovine leukemia virus envelope gene: possible effects of selection and escape. Virology 2007, 366, 150–165.

194. Rodríguez, S.M.; Golemba, M.D.; Campos, R.H.; Trono, K.; Jones, L.R. Bovine leukemia virus can be classified into seven genotypes: evidence for the existence of two novel clades. J. Gen. Virol. 2009, 90, 2788–2797.

195. Moratorio, G.; Obal, G.; Dubra, A.; Correa, A.; Bianchi, S.; Buschiazzo, A.; Cristina, J.; Pritsch, O. Phylogenetic analysis of bovine leukemia viruses isolated in South America reveals diversification in seven distinct genotypes. Arch. Virol. 2010, 155, 481–489.

196. Matsumura, K.; Inoue, E.; Osawa, Y.; Okazaki, K. Molecular epidemiology of bovine leukemia virus associated with enzootic bovine leukosis in Japan. Virus Res. 2011, 155, 343–348.

197. Bruck, C.; Mathot, S.; Portetelle, D.; Berte, C.; Franssen, J.D.; Herion, P.; Burny, A. Monoclonal antibodies define eight independent antigenic regions on the bovine leukemia virus (BLV) envelope glycoprotein gp51. Virology 1982, 122, 342–352.
198. Bruck, C.; Portetelle, D.; Burny, A.; Zavada, J. Topographical analysis by monoclonal antibodies of BLV-gp51 epitopes involved in viral functions. *Virology* **1982**, *122*, 353–362.

199. Bruck, C.; Portetelle, D.; Mammerickx, M.; Mathot, S.; Burny, A. Epitopes of bovine leukemia virus glycoprotein gp51 recognized by sera of infected cattle and sheep. *Leuk. Res.* **1984**, *8*, 315–321.

200. Bruck, C.; Rensonnet, N.; Portetelle, D.; Cleuter, Y.; Mammerickx, M.; Burny, A.; Mamoun, R.; Guillemaun, B.; van der Maaten, M.J.; Ghysdael, J. Biologically active epitopes of bovine leukemia virus glycoprotein gp51: Their dependence on protein glycosylation and genetic variability. *Virology* **1984**, *136*, 20–31.

201. Portetelle, D.; Bruck, C.; Mammerickx, M.; Burny, A. In animals infected by bovine leukemia virus (BLV) antibodies to envelope glycoprotein gp51 are directed against the carbohydrate moiety. *Virology* **1980**, *105*, 223–233.

202. Portetelle, D.; Couez, D.; Bruck, C.; Kettmann, R.; Mammerickx, M.; Van der Maaten, M.; Brasseur, R.; Burny, A. Antigenic variants of bovine leukemia virus (BLV) are defined by amino acid substitutions in the NH2 part of the envelope glycoprotein gp51. *Virology* **1989**, *169*, 27–33.

203. Portetelle, D.; Dandoy, C.; Burny, A.; Zavada, J.; Siakkou, H.; Gras-Masse, H.; Drobecq, H.; Tartar, A. Synthetic peptides approach to identification of epitopes on bovine leukemia virus envelope glycoprotein gp51. *Virology* **1989**, *169*, 34–41.

204. Thurmond, M.C.; Carter, R.L.; Puhr, D.M.; Burridge, M.J. Decay of colostral antibodies to bovine leukemia virus with application to detection of calfhood infection. *Am. J. Vet. Res.* **1982**, *43*, 1152–1155.

205. Jacobsen, K.L.; Bull, R.W.; Miller, J.M.; Herdt, T.H.; Kaneene, J.B. Transmission of bovine leukemia virus: prevalence of antibodies in precolostral calves. *Prev. Vet. Med.* **1983**, *1*, 265–272.

206. Lassauzet, M.L.; Johnson, W.O.; Thurmond, M.C.; Stevens, F. Factors associated with decay of colostral antibodies to bovine leukemia virus infection. *Prev. Vet. Med.* **1990**, *9*, 45–58.

207. Nagy, D.W.; Tyler, J.W.; Kleiboeker, S.B. Decreased periparturient transmission of bovine leukosis virus in colostrum-fed calves. *J. Vet. Intern. Med.* **2007**, *21*, 1104–1107.

208. Kono, Y.; Arai, K.; Sentsui, H.; Matsukawa, S.; Itohara, S. Protection against bovine leukemia virus infection in sheep by active and passive immunization. *Nippon Juigaku Zasshi* **1986**, *48*, 117–125.

209. Portetelle, D.; Limbach, K.; Burny, A.; Mammerickx, M.; Desmettre, P.; Riviere, M.; Zavada, J.; Paoletti, E. Recombinant vaccinia virus expression of the bovine leukaemia virus envelope gene and protection of immunized sheep against infection. *Vaccine* **1991**, *9*, 194–200.

210. Gatei, M.H.; Naif, H.M.; Kumar, S.; Boyle, D.B.; Daniel, R.C.; Good, M.F.; Lavin, M.F. Protection of sheep against bovine leukemia virus (BLV) infection by vaccination with recombinant vaccinia viruses expressing BLV envelope glycoproteins: Correlation of protection with CD4 T-cell response to gp51 peptide 51-70. *J. Virol.* **1993**, *67*, 1803–1810.

211. Burny, A. Comparative approach to retroviral vaccines. *AIDS Res. Hum. Retroviruses* **1996**, *12*, 389–392.

212. Kumar, S.; Andrew, M.E.; Boyle, D.B.; Brandon, R.B.; Lavin, M.F.; Daniel, R.C. Expression of bovine leukaemia virus envelope gene by recombinant vaccinia viruses. *Virus Res.* **1990**, *17*, 131–142.
213. Ohishi, K.; Suzuki, H.; Maruyama, T.; Yamamoto, T.; Funahashi, S.; Miki, K.; Ikawa, Y.; Sugimoto, M. Induction of neutralizing antibodies against bovine leukosis virus in rabbits by vaccination with recombinant vaccinia virus expressing bovine leukosis virus envelope glycoprotein. *Am. J. Vet. Res.* **1990**, *51*, 1170–1173.

214. Ohishi, K.; Suzuki, H.; Yamamoto, T.; Maruyama, T.; Miki, K.; Ikawa, Y.; Numakunai, S.; Okada, K.; Ohshima, K.; Sugimoto, M. Protective immunity against bovine leukaemia virus (BLV) induced in carrier sheep by inoculation with a vaccinia virus-BLV env recombinant: association with cell-mediated immunity. *J. Gen. Virol.* **1991**, *72*, 1887–1892.

215. Okada, K.; Ikeyama, S.; Ohishi, K.; Suzuki, H.; Sugimoto, M.; Numakunai, S.; Chiba, T.; Murakami, K.; Davis, W.C.; Ohshima, K.; *et al.* Involvement of CD8+ T cells in delayed-type hypersensitivity responses against bovine leukemia virus (BLV) induced in sheep vaccinated with recombinant vaccinia virus expressing BLV envelope glycoprotein. *Vet. Pathol.* **1993**, *30*, 104–110.

216. Ohishi, K.; Ikawa, Y. T cell-mediated destruction of bovine leukemia virus-infected peripheral lymphocytes by bovine leukemia virus env-vaccinia recombinant vaccine. *AIDS Res. Hum. Retroviruses* **1996**, *12*, 393–398.

217. Ohishi, K.; Suzuki, H.; Yasutomi, Y.; Onuma, M.; Okada, K.; Numakunai, S.; Ohshima, K.; Ikawa, Y.; Sugimoto, M. Augmentation of bovine leukemia virus (BLV)-specific lymphocyte proliferation responses in ruminants by inoculation with BLV env-recombinant vaccinia virus: their role in the suppression of BLV replication. *Microbiol. Immunol.* **1992**, *36*, 1317–1323.

218. Cherney, T.M.; Schultz, R.D. Viral status and antibody response in cattle inoculated with recombinant bovine leukemia virus-vaccinia virus vaccines after challenge exposure with bovine leukemia virus-infected lymphocytes. *Am. J. Vet. Res.* **1996**, *57*, 812–818.

219. Von Beust, B.R.; Brown, W.C.; Estes, D.M.; Zarlanga, D.S.; McElwain, T.F.; Palmer, G.H. Development and *in vitro* characterization of recombinant vaccinia viruses expressing bovine leukemia virus gp51 in combination with bovine IL4 or IL12. *Vaccine* **1999**, *17*, 384–395.

220. Callebaut, I.; Mormon, J.P.; Burny, A.; Portetelle, D. The bovine leukemia virus (BLV) envelope glycoprotein gp51 as a general model for the design of a subunit vaccine against retroviral infection: Mapping of functional sites through immunological and structural data. *Leukemia* **1994**, *8*, 218–221.

221. Ohishi, K.; Kabeya, H.; Amanuma, H.; Onuma, M. Induction of bovine leukaemia virus Env-specific Th-1 type immunity in mice by vaccination with short synthesized peptide-liposome. *Vaccine* **1996**, *14*, 1143–1148.

222. Ohishi, K.; Kabeya, H.; Amanuma, H.; Onuma, M. Peptide-based bovine leukemia virus (BLV) vaccine that induces BLV-Env specific Th-1 type immunity. *Leukemia* **1997**, *11*, 223–226.

223. Okada, K.; Sonoda, K.; Koyama, M.; Yin, S.; Ikeda, M.; Goryo, M.; Chen, S.L.; Kabeya, H.; Ohishi, K.; Onuma, M. Delayed-type hypersensitivity in sheep induced by synthetic peptides of bovine leukemia virus encapsulated in mannan-coated liposome. *J. Vet. Med. Sci.* **2003**, *65*, 515–518.

224. Hislop, A.D.; Good, M.F.; Mateo, L.; Gardner, J.; Gatei, M.H.; Daniel, R.C.; Meyers, B.V.; Lavin, M.F.; Suhrbier, A. Vaccine-induced cytotoxic T lymphocytes protect against retroviral challenge. *Nat. Med.* **1998**, *4*, 1193–1196.
225. Mateo, L.; Gardner, J.; Suhrbier, A. Delayed emergence of bovine leukemia virus after vaccination with a protective cytotoxic T cell-based vaccine. *AIDS Res. Hum. Retroviruses*. **2001**, *17*, 1447–1453.

226. Brillowska, A.; Dabrowski, S.; Rulka, J.; Kubis, P.; Buzala, E.; Kur, J. Protection of cattle against bovine leukemia virus (BLV) infection could be attained by DNA vaccination. *Acta Biochim. Pol.* **1999**, *46*, 971–976.

227. Usui, T.; Konnai, S.; Tajima, S.; Watarai, S.; Aida, Y.; Ohashi, K.; Onuma, M. Protective effects of vaccination with bovine leukemia virus (BLV) Tax DNA against BLV infection in sheep. *J. Vet. Med. Sci.* **2003**, *65*, 1201–1205.

228. Sakakibara, N.; Kabeya, H.; Ohashi, K.; Sugimoto, C.; Onuma, M. Epitope mapping of bovine leukemia virus transactivator protein tax. *J. Vet. Med. Sci.* **1998**, *60*, 599–605.

229. Van den Broeke, A.; Oumouna, M.; Beskorwayne, T.; Szynal, M.; Cleuter, Y.; Babiuk, S.; Bagnis, C.; Martiat, P.; Burny, A.; Griebel, P. Cytotoxic responses to BLV tax oncoprotein do not prevent leukemogenesis in sheep. *Leuk. Res.* **2010**, *34*, 1663–1669.

230. Boris-Lawrie, K.; Temin, H.M. Genetically simpler bovine leukemia virus derivatives can replicate independently of Tax and Rex. *J. Virol.* **1995**, *69*, 1920–1924.

231. Boris-Lawrie, K.; Altanerova, V.; Altaner, C.; Kucerova, L.; Temin, H.M. *In vivo* study of genetically simplified bovine leukemia virus derivatives that lack tax and rex. *J. Virol.* **1997**, *71*, 1514–1520.

232. Kucerova, L.; Altanerova, V.; Altaner, C.; Boris-Lawrie, K. Bovine leukemia virus structural gene vectors are immunogenic and lack pathogenicity in a rabbit model. *J. Virol.* **1999**, *73*, 8160–8166.

233. Kerkhofs, P.; Gatot, J.S.; Knapen, K.; Manmerickx, M.; Burny, A.; Portetelle, D.; Willems, L.; Kettmann, R. Long-term protection against bovine leukaemia virus replication in cattle and sheep. *J. Gen. Virol.* **2000**, *81*, 957–963.

234. Reichert, M.; Cantor, G.H.; Willems, L.; Kettmann, R. Protective effects of a live attenuated bovine leukaemia virus vaccine with deletion in the R3 and G4 genes. *J. Gen. Virol.* **2000**, *81*, 965–969.

235. Altanerova, V.; Holicova, D.; Kucerova, L.; Altaner, C.; Lairmore, M.D.; Boris-Lawrie, K. Long-term infection with retroviral structural gene vector provides protection against bovine leukemia virus disease in rabbits. *Virology* **2004**, *329*, 434–439.

236. Debacq, C.; Sanchez Alcaraz, M.T.; Mortreux, F.; Kerkhofs, P.; Kettmann, R.; Willems, L. Reduced proviral loads during primo-infection of sheep by Bovine Leukemia virus attenuated mutants. *Retrovirology* **2004**, *1*, 31.

237. Florins, A.; Gillet, N.; Boxus, M.; Kerkhofs, P.; Kettmann, R.; Willems, L. Even attenuated bovine leukemia virus proviruses can be pathogenic in sheep. *J. Virol.* **2007**, *81*, 10195–10200.

238. Willems, L.; Kerkhofs, P.; Attenele, L.; Burny, A.; Portetelle, D.; Kettmann, R. The major homology region of bovine leukaemia virus p24gag is required for virus infectivity in vivo. *J. Gen. Virol.* **1997**, *78*, 637–640.

239. Willems, L.; Gatot, J.S.; Manmerickx, M.; Portetelle, D.; Burny, A.; Kerkhofs, P.; Kettmann, R. The YXXL signalling motifs of the bovine leukemia virus transmembrane protein are required for *in vivo* infection and maintenance of high viral loads. *J. Virol.* **1995**, *69*, 4137–4141.
240. Willems, L.; Kerkhofs, P.; Dequiedt, F.; Portetelle, D.; Mammerickx, M.; Burny, A.; Kettmann, R. Attenuation of bovine leukemia virus by deletion of R3 and G4 open reading frames. *Proc. Natl. Acad. Sci. U. S. A.* 1994, 91, 11532–11536.

241. Bartoe, J.T.; Albrecht, B.; Collins, N.D.; Robek, M.D.; Ratner, L.; Green, P.L.; Lairmore, M.D. Functional role of pX open reading frame II of human T-lymphotropic virus type 1 in maintenance of viral loads *in vivo*. *J. Virol.* 2000, 74, 1094–1100.

242. Collins, N.D.; Newbound, G.C.; Albrecht, B.; Beard, J.L.; Ratner, L.; Lairmore, M.D. Selective ablation of human T-cell lymphotropic virus type 1 p12l reduces viral infectivity *in vivo*. *Blood* 1998, 91, 4701–4707.

243. Silverman, L.R.; Phipps, A.J.; Montgomery, A.; Ratner, L.; Lairmore, M.D. Human T-cell lymphotropic virus type 1 open reading frame type 1 encoding p30II is required for *in vivo* replication: evidence of *in vivo* reversion. *J. Virol.* 2004, 78, 3837–3845.

244. Seiki, M.; Hattori, S.; Hirayama, Y.; Yoshida, M. Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. *Proc. Natl. Acad. Sci. U. S. A.* 1983, 80, 3618–3622.

245. Sagata, N.; Yasunaga, T.; Tsuzuku-Kawamura, J.; Ohishi, K.; Ogawa, Y.; Ikawa, Y. Complete nucleotide sequence of the genome of bovine leukemia virus: its evolutionary relationship to other retroviruses. *Proc. Natl. Acad. Sci. U. S. A.* 1985, 82, 677–681.

246. Matsuoka, M.; Jeang, K.T. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. *Nat. Rev. Cancer* 2007, 7, 270–280.

247. Taniguchi, Y.; Nosaka, K.; Yasunaga, J.; Maeda, M.; Mueller, N.; Okayama, A.; Matsuoka, M. Silencing of human T-cell leukemia virus type I gene transcription by epigenetic mechanisms. *Retrovirology* 2005, 2, 64.

248. Wattel, E.; Cavrois, M.; Gessain, A.; Wain-Hobson, S. Clonal expansion of infected cells: a way of life for HTLV-I. *J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.* 1996, 13, 92–99.

249. Mortreux, F.; Leclercq, I.; Gabet, A.S.; Leroy, A.; Westhof, E.; Gessain, A.; Wain-Hobson, S.; Wattel, E. Somatic mutation in human T-cell leukemia virus type 1 provirus and flanking cellular sequences during clonal expansion *in vivo*. *J. Natl. Cancer Inst.* 2001, 93, 367–377.

250. Sibon, D.; Gabet, A.S.; Zandecki, M.; Pinatel, C.; Thete, J.; Delfau-Larue, M.H.; Rabaaoui, S.; Gessain, A.; Gout, O.; Jacobson, S.; Mortreux, F.; Wattel, E. HTLV-1 propels untransformed CD4 lymphocytes into the cell cycle while protecting CD8 cells from death. *J. Clin. Invest.* 2006, 116, 974–983.

251. Willems, L.; Gegonne, A.; Chen, G.; Burny, A.; Kettmann, R.; Ghysdael, J. The bovine leukemia virus p34 is a transactivator protein. *EMBO J.* 1987, 6, 3385–3389.

252. Willems, L.; Heremans, H.; Chen, G.; Portetelle, D.; Billiau, A.; Burny, A.; Kettmann, R. Cooperation between bovine leukaemia virus transactivator protein and Ha-ras oncogene product in cellular transformation. *EMBO J.* 1990, 9, 1577–1581.

253. Burny, A.; Cleuter, Y.; Couez, D.; Dandoy, C.; Gras-Masse, H.; Gregoire, D.; Kettmann, R.; Mammerickx, M.; Marbaix, G.; Portetelle, D.; et al. Bovine leukemia Virus (BLV) as a model system for human lymphotropic virus (HTLV) and HTLV as a model for BLV. In Proceedings of the XIIth Symposium for Comparative Research on Leukemia and Related Diseases, Hamburg, Germany, 7–11 July 1985; pp. 336–348.
254. Willems, L.; Burny, A.; Dangoisse, O.; Dequiedt, F.; Gatot, J.S.; Kerkhofs, P.; Lefebvre, L.; Mereza k, C.; Portatelle, D.; Twizere, J.C.; Kettmann, R. Bovine leukemia virus as a model for the human T-cell leukemia. *Curr. Top. Virol.* 1999, 16, 1787–1795.

255. Willems, L. Bovine leukemia virus as a model for studying human leukemias. *Bull. Mem. Acad. R. Med. Belg.* 2004, 159, 473–478.

256. Lezin, A.; Olindo, S.; Belrose, G.; Signate, A.; Cesaire, R.; Smadja, D.; Macallan, D.; Asquith, B.; Bangham, C.; Bouzar, A.; et al. Gene activation therapy: from the BLV model to HAM/TSP patients. *Front. Biosci.* 2009, 1, 205–215.

257. Boxus, M.; Willems, L. Mechanisms of HTLV-1 persistence and transformation. *Br. J. Cancer* 2009, 101, 1497–1501.

258. Diamond, G.A.; Denton, T.A. Alternative perspectives on the biased foundations of medical technology assessment. *Ann. Intern. Med.* 1993, 118, 455–464.

259. Nakano, S.; Ando, Y.; Saito, K.; Moriyama, I.; Ichijo, M.; Toyama, T.; Sugamura, K.; Imai, J.; Hinuma, Y. Primary infection of Japanese infants with adult T-cell leukaemia-associated retrovirus (ATLV): evidence for viral transmission from mothers to children. *J. Infect.* 1986, 12, 205–212.

260. Hino, S.; Yamaguchi, K.; Katamine, S.; Sugiyama, H.; Amagasaki, T.; Kinoshita, K.; Yoshida, Y.; Doi, H.; Tsuji, Y.; Miyamoto, T. Mother-to-child transmission of human T-cell leukemia virus type I. *Jpn. J. Cancer Res.* 1985, 76, 474–480.

261. Ando, Y.; Nakano, S.; Saito, K.; Shimamoto, I.; Ichijo, M.; Toyama, T.; Hinuma, Y. Transmission of adult T-cell leukemia retrovirus (HTLV-I) from mother to child: Comparison of bottle- with breast-fed babies. *Jpn. J. Cancer Res.* 1987, 78, 322–324.

262. Kusuhara, K.; Sonoda, S.; Takahashi, K.; Tokugawa, K.; Fukushima, J.; Ueda, K. Mother-to-child transmission of human T-cell leukemia virus type I (HTLV-I): A fifteen-year follow-up study in Okinawa, Japan. *Int. J. Cancer* 1987, 40, 755–757.

263. Kinoshita, K.; Hino, S.; Amagasaki, T.; Ikeda, S.; Yamada, Y.; Suzuyama, J.; Momita, S.; Toriya, K.; Kamihira, S.; Ichimaru, M. Demonstration of adult T-cell leukemia virus antigen in milk from three sero-positive mothers. *Gann* 1984, 75, 103–105.

264. Takeuchi, H.; Takahashi, M.; Norose, Y.; Takeshita, T.; Fukunaga, Y.; Takahashi, H. Transformation of breast milk macrophages by HTLV-I: Implications for HTLV-I transmission via breastfeeding. *Biomed. Res.* 2010, 31, 53–61.

265. Takahashi, K.; Takezaki, T.; Oki, T.; Kawakami, K.; Yashiki, S.; Fujiyoshi, T.; Usuku, K.; Mueller, N.; Osame, M.; Miyata, K.; et al. Inhibitory effect of maternal antibody on mother-to-child transmission of human T-lymphotropic virus type I. The Mother-to-Child Transmission Study Group. *Int. J. Cancer* 1991, 49, 673–677.

266. Takezaki, T.; Tajima, K.; Ito, M.; Ito, S.; Kinoshita, K.; Tachibana, K.; Matsushita, Y., Short-term breast-feeding may reduce the risk of vertical transmission of HTLV-I. The Tsushima ATL Study Group. *Leukemia* 1997, 11, 60–62.

267. Wiktor, S.Z.; Pate, E.J.; Rosenberg, P.S.; Barnett, M.; Palmer, P.; Medeiros, D.; Maloney, E. M.; Blattner, W.A., Mother-to-child transmission of human T-cell lymphotropic virus type I associated with prolonged breast-feeding. *J. Hum. Virol.* 1997, 1, 37–44.
268. Ando, Y.; Nakano, S.; Saito, K.; Shimamoto, I.; Ichijo, M.; Toyama, T.; Hinuma, Y. Prevention of HTLV-I transmission through the breast milk by a freeze-thawing process. *Jpn. J. Cancer Res.* 1986, 77, 974–977.

269. Ando, Y.; Kakimoto, K.; Tanigawa, T.; Furuki, K.; Saito, K.; Nakano, S.; Hashimoto, H.; Moriyama, I.; Ichijo, M.; Toyama, T. Effect of freeze-thawing breast milk on vertical HTLV-I transmission from seropositive mothers to children. *Jpn. J. Cancer Res.* 1989, 80, 405–407.

270. Yamato, K.; Taguchi, H.; Yoshimoto, S.; Fujishita, M.; Yamashita, M.; Ohtsuki, Y.; Hoshino, H.; Miyoshi, I. Inactivation of lymphocyte-transforming activity of human T-cell leukemia virus type I by heat. *Jpn. J. Cancer Res.* 1986, 77, 13–15.

271. Saito, S.; Furuki, K.; Ando, Y.; Tanigawa, T.; Kakimoto, K.; Moriyama, I.; Ichijo, M. Identification of HTLV-I sequence in cord blood mononuclear cells of neonates born to HTLV-I antigen/antibody-positive mothers by polymerase chain reaction. *Jpn. J. Cancer Res.* 1990, 81, 890–895.

272. Tajima, K.; Tominaga, S.; Suchi, T.; Kawagoe, T.; Komoda, H.; Hinuma, Y.; Oda, T.; Fujita, K. Epidemiological analysis of the distribution of antibody to adult T-cell leukemia-virus-associated antigen: Possible horizontal transmission of adult T-cell leukemia virus. *Gann* 1982, 73, 893–901.

273. Kajiyama, W.; Kashiwagi, S.; Ikematsu, H.; Hayashi, J.; Nomura, H.; Okochi, K. Intrafamilial transmission of adult T cell leukemia virus. *J. Infect. Dis.* 1986, 154, 851–857.

274. Murphy, E.L.; Figueroa, J.P.; Gibbs, W.N.; Brathwaite, A.; Holding-Cobham, M.; Waters, D.; Cranston, B.; Hanchard, B.; Blattner, W.A. Sexual transmission of human T-lymphotropic virus type I (HTLV-I). *Ann. Intern. Med.* 1989, 111, 555–560.

275. Stuver, S.O.; Tachibana, N.; Okayama, A.; Shioiri, S.; Tsunetoshi, Y.; Tsuda, K.; Mueller, N. E. Heterosexual transmission of human T cell leukemia/lymphoma virus type I among married couples in southwestern Japan: an initial report from the Miyazaki Cohort Study. *J. Infect. Dis.* 1993, 167, 57–65.

276. Okochi, K.; Sato, H.; Hinuma, Y. A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: Seroconversion in recipients. *Vox Sang* 1984, 46, 245–253.

277. Sato, H.; Okochi, K. Transmission of human T-cell leukemia virus (HTLV-I) by blood transfusion: demonstration of proviral DNA in recipients' blood lymphocytes. *Int. J. Cancer* 1986, 37, 395–400.

278. Larson, C.J.; Taswell, H.F. Human T-cell leukemia virus type I (HTLV-I) and blood transfusion. *Mayo Clin. Proc.* 1988, 63, 869–875.

279. Lee, H.; Swanson, P.; Shorty, V.S.; Zack, J.A.; Rosenblatt, J.D.; Chen, I.S. High rate of HTLV-II infection in seropositive i.v. drug abusers in New Orleans. *Science* 1989, 244, 471–475.

280. Kwok, S.; Gallo, D.; Hanson, C.; McKinney, N.; Poiesz, B.; Sninsky, J.J. High prevalence of HTLV-II among intravenous drug abusers: PCR confirmation and typing. *AIDS Res. Hum. Retroviruses* 1990, 6, 561–565.

281. Zella, D.; Mori, L.; Sala, M.; Ferrante, P.; Casoli, C.; Magnani, G.; Achilli, G.; Cattaneo, E.; Lori, F.; Bertazzoni, U. HTLV-II infection in Italian drug abusers. *Lancet* 1990, 336, 575–576.

282. Khabbaz, R.F.; Hartel, D.; Lairmore, M.; Horsburgh, C.R.; Schoenbaum, E.E.; Roberts, B.; Hartley, T.M.; Friedland, G. Human T lymphotropic virus type II (HTLV-II) infection in a cohort of New York intravenous drug users: An old infection? *J. Infect. Dis.* 1991, 163, 252–256.
283. Pepin, J.; Labbe, A.C.; Mamadou-Yaya, F.; Mbelesso, P.; Mbadingai, S.; Deslandes, S.; Locas, M.C.; Frost, E. Iatrogenic transmission of human T cell lymphotropic virus type 1 and hepatitis C virus through parenteral treatment and chemoprophylaxis of sleeping sickness in colonial Equatorial Africa. *Clin. Infect. Dis.* **2010**, *51*, 777–784.

284. Morikawa, K.; Kuroda, M.; Tofuku, Y.; Uehara, H.; Akizawa, T.; Kitaoka, T.; Koshikawa, S.; Sugimoto, H.; Hashimoto, K. Prevalence of HTLV-1 antibodies in hemodialysis patients in Japan. *Am. J. Kidney Dis.* **1988**, *12*, 185–193.

285. Kauffman, H.M.; Taranto, S.E. Human T-cell lymphotropic virus type-1 and organ donors. *Transplantation* **2003**, *76*, 745–746.

286. González-Pérez, M.P.; Munoz-Juárez, L.; Cárdenas, F.C.; Zarranz Irimizaldu, J.J.; Carranceja, J.C.; García-Saiz, A. Human T-cell leukemia virus type I infection in various recipients of transplants from the same donor. *Transplantation* **2003**, *75*, 1006–1011.

287. Zarranz Imirizaldu, J.J.; Gomez Esteban, J.C.; Rouco Axpe, I.; Perez Concha, T.; Velasco Juanes, F.; Allue Susaeta, I.; Corral Carranceja, J.M. Post-transplantation HTLV-1 myelopathy in three recipients from a single donor. *J. Neurol. Neurosurg. Psychiatry* **2003**, *74*, 1080–1084.

288. Arjmand, B.; Aghayan, S.H.; Goodarzi, P.; Farzanehkhah, M.; Mortazavi, S.M.; Niknam, M.H.; Jafarian, A.; Arjmand, F.; Jebellyfar, S. Seroprevalence of human T lymphotropic virus (HTLV) among tissue donors in Iranian tissue bank. *Cell Tissue Bank* **2009**, *10*, 247–252.

289. Khameneh, Z.R.; Sepehrvand, N.; Masudi, S.; Taghizade-Afshari, A. Seroprevalence of HTLV-1 among kidney graft recipients: A single-center study. *Exp. Clin. Transplant.* **2010**, *8*, 146–149.

290. Clark, J.; Saxinger, C.; Gibbs, W.N.; Lofters, W.; Lagranade, L.; Deceulaer, K.; Ensroth, A.; Robert-Guroff, M.; Gallo, R.C.; Blattner, W.A. Seroepidemiologic studies of human T-cell leukemia/lymphoma virus type I in Jamaica. *Int. J. Cancer* **1985**, *36*, 37–41.

291. Kazanji, M.; Gessain, A. Human T-cell lymphotropic virus types I and II (HTLV-I/II) in French Guiana: Clinical and molecular epidemiology. *Cad. Saude Publica* **2003**, *19*, 1227–1240.

292. Leon, G.; Quiros, A.M.; Lopez, J.L.; Hung, M.; Diaz, A.M.; Goncalves, J.; Da Costa, O.; Hernandez, T.; Chirinos, M.; Gomez, R. Seropositivity for human T-lymphotropic virus type I and II among donors at the Municipal Blood Bank of Caracas and associated risk factors. *Rev. Panam. Salud Publica* **2003**, *13*, 117–123.

293. Sanchez-Palacios, C.; Gotuzzo, E.; Vandamme, A.M.; Maldonado, Y. Seroprevalence and risk factors for human T-cell lymphotropic virus (HTLV-I) infection among ethnically and geographically diverse Peruvian women. *Int. J. Infect. Dis.* **2003**, *7*, 132–137.

294. Gastaldello, R.; Hall, W.W.; Gallego, S. Seroepidemiology of HTLV-I/II in Argentina: an overview. *J. Acquir. Immune Defic. Syndr.* **2004**, *35*, 301–308.
298. Biglione, M.M.; Astarloa, L.; Salomon, H.E. High prevalence of HTLV-I and HTLV-II among blood donors in Argentina: A South American health concern. *AIDS Res. Hum. Retroviruses* 2005, 21, 1–4.

299. Chandia, L.; Sotomayor, C.; Ordenes, S.; Salas, P.; Navarrete, M.; Lopez, M.; Oth, C. Seroprevalence of human T-cell lymphotropic virus type 1 and 2 in blood donors from the regional hospital of Valdivia, Chile. *Med. Microbiol. Immunol.* 2005, 21, 1–4.

300. Osame, M.; Janssen, R.; Kubota, H.; Nishitani, H.; Igata, A.; Nagataki, S.; Mori, M.; Goto, I.; Shimabukuro, H.; Khabbaz, R.; et al. Nationwide survey of HTLV-I-associated myelopathy in Japan: association with blood transfusion. *Ann. Neurol.* 1990, 28, 50–56.

301. Inaba, S.; Okochi, K.; Sato, H.; Fukada, K.; Kinukawa, N.; Nakata, H.; Kinjyo, K.; Fujii, F.; Maeda, Y. Efficacy of donor screening for HTLV-I and the natural history of transfusion-transmitted infection. *Transfusion* 1999, 39, 1104–1110.

302. Polizzotto, M.N.; Wood, E.M.; Ingham, H.; Keller, A.J. Reducing the risk of transfusion-transmissible viral infection through blood donor selection: The Australian experience 2000 through 2006. *Transfusion* 2008, 48, 55–63.

303. Berini, C.A.; Gendler, S.A.; Pascuccio, S.; Eirin, M.E.; McFarland, W.; Page, K.; Carnevali, L.; Murphy, E.; Biglione, M.M. Decreasing trends in HTLV-1/2 but stable HIV-1 infection among replacement donors in Argentina. *J. Med. Virol.* 2010, 82, 873–877.

304. Lima, G.M.; Eustaquio, J.M.; Martins, R.A.; Josahkian, J.A.; Pereira Gde, A.; Moraes-Souza, H.; Martins, P.R. Decline in the prevalence of HTLV-1/2 among blood donors at the Regional Blood Center of the City of Uberaba, State of Minas Gerais, from 1995 to 2008. *Rev. Soc. Bras. Med. Trop.* 2010, 43, 421–424.

305. Bitar, N.; Hajj, H.E.; Houmani, Z.; Sabbah, A.; Otrock, Z.K.; Mahfouz, R.; Zaataari, G.; Bazarbachi, A. Adult T-cell leukemia/lymphoma in the Middle East: first report of two cases from Lebanon. *Transfusion* 2009, 49, 1859–1864.

306. Stienlauf, S.; Yahalom, V.; Schwartz, E.; Shinar, E.; Segal, G.; Sidi, Y. Epidemiology of human T-cell lymphotropic virus type 1 infection in blood donors, Israel. *Emerg. Infect. Dis.* 2009, 15, 1116–1118.

307. de The, G.; Bomford, R. An HTLV-I vaccine: Why, how, for whom? *AIDS Res. Hum. Retroviruses* 1993, 9, 381–386.

308. Bomford, R.; Kazanjii, M.; De The, G. Vaccine against human T cell leukemia-lymphoma virus type I: progress and prospects. *AIDS Res. Hum. Retroviruses* 1996, 12, 403–405.

309. Takehara, N.; Ishihara, Y.; Uemura, Y.; Sawada, T.; Ohtsuki, Y.; Iwai, H.; Hoshino, H.; Miyoshi, I. Effect of immunization on HTLV-I infection in rabbits. *Int. J. Cancer* 1989, 44, 332–336.

310. Nakamura, H.; Hayami, M.; Ohta, Y.; Ishikawa, K.; Tsujimoto, H.; Kiyokawa, T.; Yoshida, M.; Sasagawa, A.; Honjo, S. Protection of cynomolgus monkeys against infection by human T-cell leukemia virus type-I by immunization with viral env gene products produced in Escherichia coli. *Int. J. Cancer* 1987, 40, 403–407.

311. Ohashi, T.; Hanabuchi, S.; Kato, H.; Tateno, H.; Takemura, F.; Tsukahara, T.; Koya, Y.; Hasegawa, A.; Masuda, T.; Kannagi, M. Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with human T-cell leukemia virus type 1 Tax-coding DNA vaccine. *J. Virol.* 2000, 74, 9610–9616.
312. Kazanji, M.; Tartaglia, J.; Franchini, G.; de Theoisy, B.; Talarmin, A.; Contamin, H.; Gessain, A.; de The, G. Immunogenicity and protective efficacy of recombinant human T-cell leukemia/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus). *J. Virol.* **2001**, *75*, 5939–5948.

313. Baba, E.; Nakamura, M.; Ohkuma, K.; Kira, J.; Tanaka, Y.; Nakano, S.; Niho, Y. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies. *J. Immunol.* **1995**, *154*, 399–412.

314. Tanaka, Y.; Tanaka, R.; Terada, E.; Koyanagi, Y.; Miyano-Kurosaki, N.; Yamamoto, N.; Baba, E.; Nakamura, M.; Shida, H. Induction of antibody responses that neutralize human T-cell leukemia virus type I infection in vitro and in vivo by peptide immunization. *J. Virol.* **1994**, *68*, 6323–6331.

315. Hanabuchi, S.; Ohashi, T.; Koya, Y.; Kato, H.; Hasegawa, A.; Takemura, F.; Masuda, T.; Kannagi, M. Regression of human T-cell leukemia virus type I (HTLV-I)-associated lymphomas in a rat model: Peptide-induced T-cell immunity. *J. Natl. Cancer Inst.* **2001**, *93*, 1775–1783.

316. Sundaram, R.; Lynch, M.P.; Rawale, S.; Dakappagari, N.; Young, D.; Walker, C.M.; Lemonnier, F.; Jacobson, S.; Kaumaya, P.T. Protective efficacy of multiepitope human leukocyte antigen-A*0201 restricted cytotoxic T-lymphocyte peptide construct against challenge with human T-cell lymphotropic virus type I Tax recombinant vaccinia virus. *J. Acquir. Immune Defic. Syndr.* **2004**, *37*, 1329–1339.

317. Sundaram, R.; Sun, Y.; Walker, C.M.; Lemonnier, F.A.; Jacobson, S.; Kaumaya, P.T. A novel multivalent human CTL peptide construct elicits robust cellular immune responses in HLA-A*0201 transgenic mice: implications for HTLV-1 vaccine design. *Vaccine* **2003**, *21*, 2767–2781.

318. Kobayashi, H.; Ngato, T.; Sato, K.; Aoki, N.; Kimura, S.; Tanaka, Y.; Aizawa, H.; Tateno, M.; Celis, E. *In vitro* peptide immunization of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes. *Clin. Cancer Res.* **2006**, *12*, 3814–3822.

319. Kozako, T.; Hirata, S.; Shimizu, Y.; Satoh, Y.; Yoshimitsu, M.; White, Y.; Lemonnier, F.; Shimeno, H.; Soeda, S.; Arima, N. Oligomannose-coated liposomes efficiently induce human T-cell leukemia virus-1-specific cytotoxic T lymphocytes without adjuvant. *FEBS J.* **2011**, *278*, 1358–1366.

320. Kozako, T.; Fukada, K.; Hirata, S.; White, Y.; Harao, M.; Nishimura, Y.; Kino, Y.; Soeda, S.; Shimeno, H.; Lemonnier, F.; Sonoda, S.; Arima, N. Efficient induction of human T-cell leukemia virus-1-specific CTL by chimeric particle without adjuvant as a prophylactic for adult T-cell leukemia. *Mol. Immunol.* **2009**, *47*, 460–613.

321. Conrad, S.F.; Byeon, I.J.; DiGeorge, A.M.; Lairmore, M.D.; Tsai, M.D.; Kaumaya, P.T. Immunogenicity and conformational properties of an N-linked glycosylated peptide epitope of human T-lymphotropic virus type 1 (HTLV-I). *Biomed. Pept. Proteins Nucleic Acids* **1995**, *1*, 83–92.

322. Frangione-Beebe, M.; Albrecht, B.; Dakappagari, N.; Rose, R.T.; Brooks, C.L.; Schwendeman, S.P.; Lairmore, M.D.; Kaumaya, P.T. Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide. *Vaccine* **2000**, *19*, 1068–1081.
323. Kazanji, M.; Heraud, J.M.; Merien, F.; Pique, C.; de The, G.; Gessain, A.; Jacobson, S. Chimeric peptide vaccine composed of B- and T-cell epitopes of human T-cell leukemia virus type 1 induces humoral and cellular immune responses and reduces the proviral load in immunized squirrel monkeys (Saimiri sciureus). *J. Gen. Virol.* **2006**, *87*, 1331–1337.

324. Shida, H.; Tochikura, T.; Sato, T.; Konno, T.; Hirayoshi, K.; Seki, M.; Ito, Y.; Hatanaka, M.; Hinuma, Y.; Sugimoto, M.; *et al.* Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection. *EMBO J.* **1987**, *6*, 3379–3384.

325. Hakoda, E.; Machida, H.; Tanaka, Y.; Morishita, N.; Sawada, T.; Shida, H.; Hoshino, H.; Miyoshi, I. Vaccination of rabbits with recombinant vaccinia virus carrying the envelope gene of human T-cell lymphotropic virus type I. *Int. J. Cancer* **1995**, *60*, 567–570.

326. Franchini, G.; Benson, J.; Gallo, R.; Paoletti, E.; Tartaglia, J. Attenuated poxvirus vectors as carriers in vaccines against human T cell leukemia-lymphoma virus type I. *AIDS Res. Hum. Retroviruses* **1996**, *12*, 407–408.

327. Franchini, G.; Tartaglia, J.; Markham, P.; Benson, J.; Fullen, J.; Wills, M.; Arp, J.; Dekaban, G.; Paoletti, E.; Gallo, R.C. Highly attenuated HTLV type Ienv poxvirus vaccines induce protection against a cell-associated HTLV type I challenge in rabbits. *AIDS Res. Hum. Retroviruses* **1995**, *11*, 307–313.

328. Ibuki, K.; Funahashi, S.I.; Yamamoto, H.; Nakamura, M.; Igarashi, T.; Miura, T.; Ido, E.; Hayami, M.; Shida, H. Long-term persistence of protective immunity in cynomolgus monkeys immunized with a recombinant vaccinia virus expressing the human T cell leukaemia virus type I envelope gene. *J. Gen. Virol.* **1997**, *78*, 147–152.

329. Kazanji, M.; Bomford, R.; Bessereau, J.L.; Schulz, T.; de The, G. Expression and immunogenicity in rats of recombinant adenovirus 5 DNA plasmids and vaccinia virus containing the HTLV-I env gene. *Int. J. Cancer* **1997**, *71*, 300–307.

330. Kchour, G.; Makhoul, N.J.; Mahmoudi, M.; Kooshyar, M.M.; Shirdel, A.; Rastin, M.; Rafatpanah, H.; Tarhini, M.; Zalloua, P.A.; Hermine, O.; Farid, R.; Bazarbachi, A. Zidovudine and interferon-alpha treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran. *Leuk. Lymphoma* **2007**, *48*, 330–336.

331. Tsukasaki, K.; Hermine, O.; Bazarbachi, A.; Ratner, L.; Ramos, J.C.; Harrington, W., Jr.; O’Mahony, D.; Janik, J.E.; Bittencourt, A.L.; Taylor, G.P.; *et al.* Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: A proposal from an international consensus meeting. *J. Clin. Oncol.* **2009**, *27*, 453–459.